Published in final edited form as:

Recent Results Cancer Res. 2014 ; 193: 227–268. doi:10.1007/978-3-642-38965-8_13.

Molecular Biology of Human Herpesvirus 8: Novel Functions and Virus–Host Interactions Implicated in Viral Pathogenesis and Replication

Emily Cousins and John Nicholas

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21287, USA

Abstract

Human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus (KSHV), is the second identified human gammaherpesvirus. Like its relative Epstein-Barr virus, HHV-8 is linked to B-cell tumors, specifically primary effusion lymphoma and multicentric Castleman’s disease, in addition to endothelial-derived KS. HHV-8 is unusual in its possession of a plethora of “accessory” genes and encoded proteins in addition to the core, conserved herpesvirus and gammaherpesvirus genes that are necessary for basic biological functions of these viruses. The HHV-8 accessory proteins specify not only activities deducible from their cellular protein homologies but also novel, unsuspected activities that have revealed new mechanisms of virus–host interaction that serve virus replication or latency and may contribute to the development and progression of virus-associated neoplasia. These proteins include viral interleukin-6 (vIL-6), viral chemokines (vCCLs), viral G protein–coupled receptor (vGPCR), viral interferon regulatory factors (vIRFs), and viral antiapoptotic proteins homologous to FLICE (FADD-like IL-1 β converting enzyme)-inhibitory protein (FLIP) and survivin. Other HHV-8 proteins, such as signaling membrane receptors encoded by open reading frames K1 and K15, also interact with host mechanisms in unique ways and have been implicated in viral pathogenesis. Additionally, a set of micro-RNAs encoded by HHV-8 appear to modulate expression of multiple host proteins to provide conditions conducive to virus persistence within the host and could also contribute to HHV-8-induced neoplasia. Here, we review the molecular biology underlying these novel virus–host interactions and their potential roles in both virus biology and virus-associated disease.

1 Introduction

Human herpesvirus 8 (HHV-8) is classified as a gamma-2 herpesvirus and is related to Epstein-Barr virus (EBV), a member of the gamma-1 subfamily. One important aspect of the gammaherpesviruses is their association with neoplasia, either naturally or in animal model systems. HHV-8 is associated with B-cell–derived primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD) as well as endothelial-derived Kaposi’s sarcoma (KS) (Arvanitakis et al. 1996; Carbone et al. 2000; Chang and Moore 1996; Gaidano et al.

1997). EBV is associated with a number of B-cell malignancies, such as Burkitt's lymphoma, Hodgkin's lymphoma, and posttransplant lymphoproliferative disease, in addition to epithelial nasopharyngeal and gastric carcinomas, T-cell lymphoma, and muscle tumors (Kawa 2000; Okano 2000; Young and Murray 2003). Despite the similarities between the viruses and their associated malignancies, the particular protein functions and activities involved in the relevant aspects of virus biology and neoplasia appear to be quite distinct. Indeed, HHV-8 specifies a number of proteins that had not previously been identified in gammaherpesviruses, herpesviruses, or even viruses in general, and these proteins are believed to play vital functions in virus biology and to be centrally involved in viral pathogenesis.

One such gene is viral interleukin-6 (vIL-6), which was immediately upon its discovery implicated as a candidate contributor to HHV-8 pathogenesis (Moore et al. 1996; Neipel et al. 1997a; Nicholas et al. 1997). Previous reports had indicated that IL-6 was produced by and supported the growth of KS cells, promoted inflammation and angiogenesis typical of KS, served as an important B-cell growth factor, and was found at elevated levels in MCD patient sera (Burger et al. 1994; Ishiyama et al. 1994; Miles et al. 1990; Roth 1991; Yoshizaki et al. 1989). Similarly, the discovery of viral chemokines, vCCLs 1-3, and demonstration of their pro-angiogenic activities in experimental systems suggested that these proteins also could contribute to disease, in addition to their suspected roles in immune evasion during HHV-8 productive replication (Boshoff et al. 1997; Stine et al. 2000). The chemokine receptor homologue, vGPCR, was found to induce angiogenic cellular cytokines of the type produced in and suspected to promote the growth of KS lesions (Cannon et al. 2003; Pati et al. 2001; Schwarz and Murphy 2001). The constitutively active membrane receptors encoded by HHV-8 open reading frames (ORFs) K1 and K15 could function similarly (Brinkmann et al. 2007; Caselli et al. 2007; Samaniego et al. 2001; Wang et al. 2006). vGPCR and K1 also acted as oncogenes, promoting cell transformation and inducing tumorigenesis in animal models (Bais et al. 1998; Lee et al. 1998b; Yang et al. 2000). However, like the v-cytokines, vGPCR and K1 are expressed predominantly or exclusively during productive, lytic replication; therefore, any contributions to malignant pathogenesis are likely to be mediated through paracrine signaling. There is ample evidence that cytokine-mediated paracrine signal transduction plays a role in KS, and B-cell growth can also be influenced by this route, as discussed below. Apart from the likely involvement of these viral proteins in HHV-8-associated pathogenesis, the roles of some of these "unique" viral products in virus biology are only beginning to be appreciated. For example, the prosurvival signaling induced by vCCLs and vGPCR and the antiapoptotic activities of vIRF-1 have been demonstrated to enhance productive replication. Therefore, functions that serve normal virus biology, such as inhibiting infection-induced apoptosis, may have the "side effect" of promoting virus-associated neoplasia. This concept is familiar to viral oncologists, but the precise mechanisms deployed by HHV-8 are novel.

Classical oncogene and tumor suppressor activities are mediated in an autocrine fashion, and viral genes expressed during latency are potential contributors to malignant disease. Chief among these for HHV-8 is the latency-associated nuclear antigen, LANA, which specifies essential replication and genome segregation activities in dividing cells and impacts several host pathways to promote cell survival and proliferation (Verma et al. 2007). These

activities have obvious connections to processes involved in malignant transformation. Likewise, the viral homologue of cellular FLICE-inhibitory protein, vFLIP, is both latently expressed and crucially important for maintaining cell viability. vFLIP acts via induction of NF- κ B activity and associated antiapoptotic mechanisms, rather than via inhibition of receptor-mediated caspase activation (Chugh et al. 2005; Guasparri et al. 2004). Latency genes v-cyclin (ORF72) and micro-RNAs (miRNAs) have also been implicated in viral pathogenesis (Gottwein et al. 2011; Liang et al. 2012; Suffert et al. 2011; Verschuren et al. 2004). In addition to these latency products, vIL-6, vIRF-1, vIRF-3, K1, and K15, while expressed maximally during productive replication, have also been detected in latently infected cells (of some types) and may contribute in a direct, autocrine fashion to viral neoplasia. The interplay between lytic and latent activities is likely to be important for KS, in which cytokine dysregulation is believed to drive the disease, and this interplay may also be significant in PEL and MCD. These issues and details of the molecular biology of virus–host interactions involving these various HHV-8-encoded factors are the topic of this review.

2 HHV-8 Latency Products and Autocrine Dysregulation

2.1 Latency-Associated Nuclear Antigen (LANA)

LANA is specified by ORF73 of HHV-8, and homologues are encoded by every other sequenced member of the gamma-2 herpesvirus subfamily. The basic functions of each of these proteins are to serve as a latency origin-binding protein and to tether viral genomes to host chromosomes for appropriate segregation to daughter cell nuclei during cell division (Barbera et al. 2006; Verma et al. 2007). These activities are equivalent to those of EBNA1 of gamma-1 subfamily Epstein-Barr virus (Lindner and Sugden 2007). However, LANA has further activities that are likely to play roles in viral pathogenesis in addition to contributing to the maintenance of HHV-8 latency.

One such property reported for LANA is its association with and inhibition of the cell cycle checkpoint protein and tumor suppressor p53 (Friborg et al. 1999). However, while the presence of wild-type p53 in most PEL cell lines suggests that inactivation of p53 could be biologically relevant, the susceptibility of PEL cells to p53 activation indicates that LANA is not fully able to inhibit the tumor suppressor (Chen et al. 2010; Petre et al. 2007). LANA also interacts with retinoblastoma protein (Rb) to mediate activation of E2F-responsive targets and can transform rat embryo fibroblasts in combination with transduced H-Ras (Radkov et al. 2000). Additionally, LANA was found to suppress cyclin-dependent kinase inhibitor p16INK4a-mediated cell cycle arrest and to induce E2F-mediated S-phase entry in lymphoid cells (An et al. 2005). However, as in the case of p53, the actual relevance of this experimental finding has been questioned because Rb function appears to be fully intact in PEL cells (Platt et al. 2002).

LANA also interacts with GSK3 β , a kinase that targets various proteins involved in cell cycle regulation. GSK3 β targets include the transcriptional regulator β -catenin and proto-oncoprotein c-Myc; phosphorylation of these proteins by GSK3 β promotes their proteolytic degradation (Karim et al. 2004; Sears et al. 2000). β -catenin, in combination with the transcription factor TCF, induces expression of various genes, including c-myc, c-jun, and

cyclin D1; these genes are involved in cell cycle promotion and are dysregulated in oncogenesis. LANA binding of GSK3 β leads to nuclear sequestration and inactivation of the kinase, removing its negative regulation of β -catenin and promoting cell proliferation (Fujimuro and Hayward 2003; Fujimuro et al. 2003; Liu et al. 2007a, b). c-Myc residue T-58, the target of GSK3 β phosphorylation, was found to be hypophosphorylated in PEL cells, and this underphosphorylation and consequent stabilization of c-Myc were dependent on LANA expression (Bubman et al. 2007). In addition, LANA interacts directly with c-Myc and induces ERK-mediated activation of c-Myc via phosphorylation of residue S-62 (Liu et al. 2007b). LANA binding of c-Myc and activation of ERK activity occur independently of LANA interaction with GSK3 β . Thus, through these various interactions, LANA can activate proliferative pathways of likely significance to both HHV-8 latency and pathogenesis.

Recently, LANA has been reported to induce and interact with angiogenin (ANG), a mediator of angiogenesis, which itself upregulates LANA expression and appears to play a role in the establishment of latency and promotion of cell viability (Paudel et al. 2012; Sadagopan et al. 2011). Furthermore, interaction of LANA and ANG with annexin A2 has been identified in both HHV-8 latently infected-telomerase immortalized endothelial (TIME) cells and BCBL-1 PEL cells. Based on results from confocal analyses, it appears that these proteins colocalize and can form complexes together in addition to establishing separate ANG-LANA and ANG-annexin A2 interactions (Paudel et al. 2012). Annexin A2 is involved in regulation of cell proliferation, apoptosis, and cytoskeletal reorganization, among other activities (Shim et al. 2007; Thomas and Augustin 2009). Suppression of annexin A2 or ANG expression in PEL cells was found to increase cell death, and depletion of annexin A2 led to decreased expression of ANG and LANA (Paudel et al. 2012; Sadagopan et al. 2011). Thus, there appears to be an integrated and functionally important relationship between LANA, ANG, and annexin A2 that promotes viability of latently infected cells. Furthermore, the increased level of ANG in HHV-8-infected cells may contribute to KS pathogenesis via induction of endothelial cell activation, migration, and angiogenesis (Sadagopan et al. 2009). While the mechanisms involved in LANA, ANG, and annexin A2 mutual regulation and functional interactions remain to be elucidated, the recently reported ANG interaction with and destabilization of p53 may be significant with respect to pro-survival effects mediated via ANG (Sadagopan et al. 2012).

In addition to the individual LANA-cellular protein interactions outlined above, LANA can mediate transcriptional regulation of cellular genes via more general mechanisms. One such mechanism involves regulation of transcriptionally suppressive DNA methylation. LANA interacts with DNA methyltransferase DNMT3a, leading to its recruitment to and methylation of LANA-targeted promoters (Shamay et al. 2006). LANA also associates with histone methyltransferase SUV39H1 and transcriptional histone deacetylase-associated corepressors mSin3, SAP30, and CIR; these interactions implicate additional mechanisms of direct, promoter-specific repression by LANA (Krithivas et al. 2000; Sakakibara et al. 2004). Such mechanisms are believed to be important for the suppression of both viral lytic and cellular gene expressions to promote latency and long-term cell viability (Verma et al. 2007). LANA-targeted epigenetic repression of specific cellular genes that are silenced in

various cancers could contribute to HHV-8-associated malignancies in addition to viral latency (Shamay et al. 2006; Ziech et al. 2010).

2.2 Viral FLICE-Inhibitory Protein (vFLIP)

HHV-8-encoded vFLIP is specified by ORF K13, and the protein is often referred to simply as K13. vFLIP/K13 is related structurally to death effector domain (DED)-containing and death receptor-interacting vFLIPs of other viruses, such as MC159L from mullosum contagiosum virus and equine herpesvirus-2 E8; these vFLIPs are protective against Fas/CD95- and TNF receptor-induced apoptosis (Bertin et al. 1997; Hu et al. 1997; Thome et al. 1997). It was reported that HHV-8 vFLIP/K13 mediated protection of mouse lymphoma and rat pheochromocytoma cell lines from Fas- and TNF α -induced apoptosis (Belanger et al. 2001; Djerbi et al. 1999). However, the unique ability of HHV-8 vFLIP/K13 to induce NF- κ B signaling and its inability to effectively suppress Fas-induced apoptosis suggest that HHV-8 vFLIP/K13 functions primarily through activation of NF- κ B rather than via death receptor/caspase inhibition (Chaudhary et al. 1999; Chugh et al. 2005; Matta and Chaudhary 2004). HHV-8 vFLIP/K13 activates NF- κ B classical and alternative pathways by interacting directly with the inhibitory κ -kinase (IKK) complexes (IKK α :IKK β $\pm$ IKK γ /Nemo) to stimulate kinase activity, leading to disruption of I κ B interaction with p50/p65-subunit NF- κ B and to protease-mediated release of RelB/p52 (active form) from RelB/p100 (Field et al. 2003; Liu et al. 2002; Matta et al. 2007). Thus, vFLIP/K13 is able to activate NF- κ B independently of upstream receptor-associated mechanisms involving signaling adaptors and kinases such as TRAFs and RIP; in doing so, vFLIP/K13 can avoid activation of JNK stress signaling (Matta et al. 2007). While it was reported that vFLIP/K13 interaction with TRAF2 is required for vFLIP/K13 binding to IKK γ in BC-3 PEL cells (Guasparri et al. 2006), TRAF2-dependent interaction between vFLIP/K13 and IKK γ and activation of JNK/AP1 signaling by vFLIP/K13 was not evident in subsequent studies (Matta et al. 2007).

NF- κ B activation by vFLIP is significant because NF- κ B is a suppressor of lytic reactivation in latently infected PEL cells, and vFLIP and NF- κ B promote survival of these cells (Brown et al. 2003; Godfrey et al. 2005; Grossmann and Ganem 2008; Guasparri et al. 2004; Keller et al. 2000; Zhao et al. 2007). These effects have clear implications for the maintenance of long-term latency and for the potential contribution of vFLIP/K13 to HHV-8 malignancies. In addition to these biological effects, NF- κ B signaling also induces pro-inflammatory and angiogenic cytokines, such as IL-6 and IL-8. These cytokines are produced by KS lesions and are predicted to promote KS pathogenesis and mediate vFLIP/K13-induced cellular proliferation and transformation in experimental systems (An et al. 2003; Grossmann et al. 2006; Sun et al. 2006). Together, these findings suggest that vFLIP/K13 contributes to both viral latency maintenance and to PEL and KS pathogenesis through the constitutive activation of pro-survival and generally antilytic NF- κ B signaling.

2.3 Kaposins

The K12 transcription unit comprises the K12 ORF and two sets of GC-rich repeat units (DR1, DR2) positioned upstream of K12 (Sadler et al. 1999). Three proteins, kaposins A, B, and C, are produced from this locus by virtue of alternative transcriptional and translational initiation. Kaposin A, corresponding to the K12 translation product, is initiated from a

conventional AUG codon in a transcript originating proximal to K12. Kaposins B and C initiate from CUG codons in different reading frames in transcripts containing the upstream repeat elements. Kaposin B is translated from DR1 and DR2 in “frame 1,” while frame 2-translated kaposin C contains DR1/2-translated sequences fused to K12. A larger, spliced transcript initiating 5-kb upstream of K12 has also been identified, and this sequence has the potential to encode non-AUG-initiated protein(s) with novel N-terminal sequences derived from codons upstream of DR2 (Li et al. 2002; Pearce et al. 2005). K12-locus transcripts are found in high abundance in latently infected cells but are induced during lytic replication (Li et al. 2002; Sadler et al. 1999; Staskus et al. 1997; Sturzl et al. 1997; Zhong et al. 1996). The relative expression of kaposins A, B, and C in different cell types and tissues varies. For example, kaposins A and C are predominant in primary PEL cells, whereas kaposin B is most abundant in the BCBL-1 cell line (Li et al. 2002). While there have been no functional studies of kaposin C, activities of kaposins A and B have been reported.

As the direct product of ORF K12, kaposin A was the first identified and studied protein of this locus. In transfection experiments, the 6-kDa protein was found to transform immortalized rat-3 and NIH3T3 cells, forming cell colony foci in culture and tumors in athymic mice (Muralidhar et al. 1998). Transformation was dependent on cytohesin-1, a guanine nucleotide exchange factor, which binds to kaposin A. This interaction promotes membrane recruitment and activity of cytohesin-1, which acts on membrane-associated target GTPases such as ARF1 (Kliche et al. 2001). Increased activities of kinases, such as cdc2, PKC, ERK, and CAM kinase II, have been detected in kaposin A-transduced cells, but the underlying mechanisms have not been established (Muralidhar et al. 2000). Studies using gene arrays and signaling assays have implicated activation of MEK/ERK, PI3K/AKT, and STAT3 pathways by kaposin A (Chen et al. 2009b). Initial immunofluorescence studies indicated possible Golgi localization of kaposin A (Muralidhar et al. 2000). However, subsequent confocal fluorescence microscopy, cell fractionation, and flow cytometry analyses detected mostly perinuclear kaposin A with some plasma membrane localization also detectable (Tomkowicz et al. 2002, 2005). A LXXLL motif resembling ligand-interacting regions of nuclear receptors was required for immortalized cell transformation, and mutation of this motif led to greatly diminished nuclear association and newly acquired cytoplasmic localization of kaposin A (Tomkowicz et al. 2005). However, both wild-type and motif-mutated kaposin A were equally capable of activating an AP1 reporter, indicating that transformation occurs via a mechanism distinct from AP1 activation. More recently, kaposin A was identified as interacting with a variant of GTP-binding protein septin-4, a protein which localizes to mitochondria and promotes apoptosis (Lin et al. 2007; Mandel-Gutfreund et al. 2011). Co-expression of kaposin A with the septin-4 variant led to suppression of septin-4 variant-induced apoptosis in transfected cells (Lin et al. 2007). Therefore, inhibition of septin-4 function may be one mechanism by which kaposin A can influence malignant pathogenesis by promoting cell survival. Normally, this activity would be expected to serve virus latency. This mechanism would be biologically significant if septin-4 was expressed and functional in HHV-8 latently infected cell types.

Kaposin B, translated from the DR repeats and K12, interacts via DR2-encoded sequences with MK2 kinase and enhances its activity (McCormick and Ganem 2005). Kaposin B binds the “C-lobe” region of MK2, a region also targeted by p38 kinase. Kaposin B binding of the

C-lobe, like its phosphorylation by p38, prevents inhibitory intramolecular association of C-lobe and C-tail sequences of MK2, which results in activation of the kinase. A single DR1 together with a single DR2 repeat, but neither element alone, is sufficient to mediate MK2 activation (McCormick and Ganem 2006). MK2 activity leads to stabilization of high-turn-over mRNAs containing AU-rich elements (AREs), and many of these mRNAs specify cytokines, such as pro-inflammatory and angiogenic IL-6. Thus, kaposin B has the potential to influence viral pathogenesis. Kaposin B is predicted to function in the maintenance of latently infected cell populations and/or expansion of latent cell pools through pro-survival and mitogenic activities of induced cellular proteins. Importantly, kaposin B stabilizes the mRNA encoding PROX1, the “master regulator” of lymphatic endothelial cell differentiation. PROX1 is targeted by ARE-binding protein HuR, and kaposin B-activated p38 kinase promotes nucleo-cytoplasmic export of HuR (Yoo et al. 2010). Reprogramming of blood endothelial cells to cells expressing lymphatic markers is induced by HHV-8 infection and is believed to be a key process in KS development (Pyakurel et al. 2006; Wang et al. 2004). Stabilization of PROX1 mRNA by kaposin B represents a mechanism by which blood-to-lymphatic endothelial reprogramming is induced by HHV-8. Thus, in addition to kaposin A, kaposin B is likely to contribute significantly to HHV-8-associated disease.

2.4 Viral Interleukin-6 (vIL-6) in PEL

Viral IL-6 (vIL-6) shares approximately 25% sequence identity with its cellular counterpart, human IL-6 (hIL-6); this viral cytokine was independently discovered by multiple groups (Moore et al. 1996; Neipel et al. 1997a; Nicholas et al. 1997). Though sequence identity between human and viral homologues is low, the cytokines adopt equivalent 4- α helical bundle structures and have similar receptor interactions and signaling activities (Boulanger et al. 2003; Chow et al. 2001; Heinrich et al. 2003; Kishimoto et al. 1995). Signaling by hIL-6 requires interaction with gp130 signal transducer and gp80 receptor subunits, which leads to Janus kinase (JAK) activation and phosphorylation, dimerization, and nuclear translocation of STATs 1 and 3 (Heinrich et al. 1998). Several groups have shown that vIL-6 utilizes the same signaling components employed by human IL-6 but that it does not require gp80 for active complex formation and can signal through tetrameric (gp130₂:vIL-6₂) or hexameric (gp130₂:gp80₂:vIL-6₂) complexes (Aoki et al. 2001; Chen and Nicholas 2006; Chow et al. 2001). Ultimately, both cytokines share functional characteristics, such as the ability to sustain the growth of IL-6-dependent cell lines (Burger et al. 1998; Nicholas et al. 1997). vIL-6, however, is distinct in its ability to signal not only through gp130 complexes located on the plasma membrane but also intracellularly within the endoplasmic reticulum (ER); vIL-6, unlike hIL-6, is secreted inefficiently and localizes in large part to the ER. These unique properties of the viral homologue are likely involved in maintenance of viral latency and important for HHV-8 pathogenicity.

Several studies have shown that vIL-6 is critical for the growth of PEL cells. While vIL-6, IL-10, and vascular endothelial growth factor (VEGF) were detected in PEL cell supernatants, only vIL-6 and IL-10 induced PEL cell proliferation (Aoki and Tosato 1999; Jones et al. 1999). The detection of vIL-6 in these cultures was initially assumed to be the result of spontaneous lytic reactivation, either full or abortive, in a small proportion of cells because vIL-6 expression is induced during productive replication. However, vIL-6 is now

known to be expressed at low levels in latent PEL cells (Chandriani and Ganem 2010; Chen et al. 2009a). Depletion of vIL-6 in these cells induces apoptosis and slows the rate of cell growth (Chen et al. 2009a). Similar growth effects were observed with intracellularly delivered single-chain antibody and peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO) directed to vIL-6 and its transcript (Kovaleva et al. 2006; Zhang et al. 2008). Fully ER-retained vIL-6 (cloned to include an ER-targeting KDEL motif) is capable of rescuing the growth effects mediated by vIL-6 depletion (Chen et al. 2009a). These data indicate a prominent role of vIL-6 intracellular, autocrine signaling in support of growth and survival of latently infected PEL cells.

The mechanism through which vIL-6 acts in the ER to promote growth and viability of PEL cells is not entirely clear, but early evidence suggests that a novel interaction with VKORC1v2 (vitamin K epoxide reductase complex subunit 1 variant 2) is critical. VKORC1v2, a protein present in the ER, was identified as a novel binding partner of vIL-6 and was found to be required for PEL cell survival (Chen et al. 2012). Depletion of VKORC1v2 yielded similar growth effects to those observed in vIL-6-depleted cultures. Furthermore, a small peptide inhibitor capable of disrupting the VKORC1v2:vIL-6 interaction recapitulated growth and apoptosis effects observed upon vIL-6 or VKORC1v2 depletion, confirming the biological relevance of the vIL-6:VKORC1v2 interaction (Chen et al. 2012). These studies suggest that the activities of this viral cytokine within the ER, acting at least in part through VKORC1v2, are important for the maintenance of the virus within latently infected B cells and that these activities contribute to viral pathogenicity.

Increased levels of phosphorylated (active) STAT3 have been detected in several PEL cell lines (Aoki et al. 2003). STAT3 is activated upon vIL-6 signaling through gp130 complexes. Depletion of STAT3 in PEL cells leads to an increase in apoptosis and a decrease in the levels of survivin (Aoki et al. 2003). Survivin is a member of the IAP (inhibitors of apoptosis) family that has been shown to inhibit apoptosis in several cancer cell lines (Ambrosini et al. 1997). These results are significant because they link antiapoptotic activities of survivin to STAT3 signaling and potentially to vIL-6. It is noteworthy, in this regard, that gp130 depletion in PEL cells leads to diminished growth and increased apoptosis in culture (E. Cousins and J. Nicholas, unpublished). In addition to vIL-6:gp130 signaling, STAT3 can also be activated by VEGF (Bartoli et al. 2000). Importantly, vIL-6 has been found to induce VEGF in experimentally transduced cell lines and to play a significant role in PEL growth and dissemination in a xenograft model (Aoki et al. 1999; Aoki and Tosato 1999). Therefore, vIL-6 is involved in a complex set of activities in PEL cells and is not only capable of initiating progrowth and survival signaling through the ER compartment (Fig. 1) but may contribute to PEL pathogenesis through activation of STAT3/survivin and VEGF signaling.

2.5 Viral Interferon Regulatory Factor-3 (vIRF-3) in PEL

HHV-8 specifies four viral interferon regulatory factor homologues, vIRFs 1-4 (Cunningham et al. 2003; Lee et al. 2009a), which serve to counter the effects of cellular IRFs and to inhibit innate responses of the cell to virus infection and productive replication (see below). While all of the vIRFs are expressed during lytic replication, consistent with

their presumed primary functions in evasion of antiviral host cell defenses, vIRF-3 is expressed as a *bona fide* latent product in PEL cells (Jenner et al. 2001; Paulose-Murphy et al. 2001; Rivas et al. 2001). As such, vIRF-3 has been referred to by some investigators as latency-associated nuclear antigen-2 (LANA2), despite its partial localization in the cytoplasm (Munoz-Fontela et al. 2005) and the absence of demonstrable latent expression in any other cell type examined. Nonetheless, in the context of PEL/B cells, vIRF-3 has the potential to impact cellular pathways that may be of biological relevance to viral latency and virus-associated pathogenesis. In common with other vIRFs, vIRF-3 can inhibit cellular IRF function. vIRF-3 does so by interfering with the transcriptional activities of IRFs 3, 5, and 7 in addition to inhibiting PKR, a pro-apoptotic kinase that is activated by interferon and dsRNA (Esteban et al. 2003; Joo et al. 2007; Lubyova and Pitha 2000; Wies et al. 2009). Importantly, vIRF-3 has also been found to interact directly with p53 to inhibit the tumor suppressor and to induce c-Myc-directed transcription (Lubyova et al. 2007; Rivas et al. 2001). vIRF-3 can also interact with and inhibit FOXO3a, a transcription factor targeting pro-apoptotic genes (Munoz-Fontela et al. 2007). These activities indicate that vIRF-3 plays a significant role in promoting cell survival and proliferation in the context of PEL and potentially in general B-cell latency. Indeed, vIRF-3 has been demonstrated to be critically important for PEL cell viability in culture, as its depletion triggers apoptosis (Wies et al. 2008). Pro-survival effects of vIRF-3 may in part be the result of its inhibition of PML-mediated repression of survivin (Marcos-Villar et al. 2009). Furthermore, vIRF-3 has recently been reported to repress CIITA transcription factor-directed expression of interferon- γ and class-II major histocompatibility complex in PEL cells (Schmidt et al. 2011). This immune evasion activity of vIRF-3 is probably vital for the long-term survival of these cells in vivo. Therefore, vIRF-3 activities are likely to be important for latency persistence in at least some cell types (where vIRF-3 is latently expressed) and are probably significant contributors to PEL malignancy.

2.6 Micro-RNAs (miRNAs)

Micro-RNAs (miRNAs) are ~22 nt non-coding RNAs that regulate the expression of mRNAs via cleavage or by inhibiting translation. miRNAs are encoded as primary miRNAs (pri-miRNAs), synthesized by RNA Polymerase II, and processed to pre-miRNAs (stem-loop structures) by the RNase III domain of DROSHA prior to nuclear export by exportin 5 (Lee et al. 2003b; Lund et al. 2004). In the cytoplasm, pre-miRNAs are cleaved into 21–24 nt double-stranded RNAs by an RNase III domain of DICER, and one strand of the miRNA duplex is then incorporated into RISC (RNA-induced silencing complex) (Bartel 2004; Lee et al. 2003b). The incorporated miRNA guides the loaded RISC to the mRNA target (Schwarz et al. 2003). Generally, the mRNA target is degraded if the miRNA is perfectly complementary to the targeted sequence. Alternatively, binding of a miRNA lacking perfect complementarity inhibits translation of the mRNA (Zeng et al. 2003).

While miRNAs have been detected in all metazoans, virus-encoded miRNAs were discovered only recently (Pfeffer et al. 2004). To date, 12 HHV-8-encoded miRNAs have been identified, termed miR-K12-1 to miR-K12-12. A total of ten of the 12 miRNAs are located between latently expressed ORFs 71 and K12 in the HHV-8 genome; miR-K12-10 is located within the ORF K12, and miR-K12-12 is within the 3'UTR of K12 (Pfeffer et al.

2005; Samols et al. 2005). All 12 of the HHV-8 miRNAs are oriented “in sense” with ORFs 71 to K12 and are expressed during latency (Cai et al. 2005). Many of the miRNAs can be detected (and some are even induced) during lytic infection (Cai et al. 2005; Umbach and Cullen 2010). Bioinformatic approaches have utilized miRNA seed sequences (nt 2-7/8 of the miRNA) to search for miRNA gene targets (Gottwein and Cullen 2010; Lu et al. 2010b; Nachmani et al. 2009; Qin et al. 2010), but these approaches yield large numbers of potential candidates. Additionally, targets with less than perfect seed sequence complementarity may be overlooked, and experimental validation of identified candidates is necessary to assess authenticity. Functional approaches involving transduction of recombinant viruses containing single or a combination of HHV-8 miRNAs and monitoring potential changes in mRNA levels via microarray have also been used (Ziegelbauer et al. 2009). More recently, immunoprecipitation of RISC and/or associated Argonaute proteins has been conducted, and microarray analysis of co-precipitated mRNAs (RIP-ChIP) has been employed (Dolken et al. 2010). These methods have identified multiple mRNA targets within the host cell. From these data, the virally-encoded miRNAs have been deduced to: (1) limit NK cell recognition of virally infected cells (Nachmani et al. 2009), (2) repress RTA expression to inhibit latent-lytic switching (Bellare and Ganem 2009; Lin et al. 2011; Lu et al. 2010a), (3) interfere with TGF β signaling (Liu et al. 2012), (4) alter NF- κ B signaling pathways (Lei et al. 2010), (5) modulate cytokine production (Abend et al. 2010), and (6) modify cell cycle progression (Gottwein and Cullen 2010). These targets and pathways are summarized in Table 1 and are discussed further below.

HHV-8 employs many strategies to remain undetected by the host immune response, and viral miRNAs are believed to play a vital role. HHV-8-encoded miR-K12-7 targets MICB, a viral infection-induced cell-surface marker that functions to induce natural killer (NK) cell recognition and killing via engagement with the NK-expressed NKG2D receptor (Glas et al. 2000; Nachmani et al. 2009). MICB targeting by virus-encoded microRNAs is conserved in human cytomegalovirus (Stern-Ginossar et al. 2007; Stern-Ginossar et al. 2008) and EBV infection (Nachmani et al. 2009). In addition to immune evasion, several HHV-8 miRNAs target RTA, thereby functioning to maintain viral latency and inhibit viral replication. Several research groups have identified miR-K12-3, miR-K12-5, miR-K12-9, and miR-K12-11 as directly or indirectly targeting RTA expression (Bellare and Ganem 2009; Lin et al. 2011; Lu et al. 2010b). Viral replication is also limited through inhibition of the NF- κ B inhibitor I κ B α by miR-K12-1; upregulation of NF- κ B signaling abrogates lytic replication of HHV-8 (Lei et al. 2010). By reducing virion production, the virus is able to further circumvent the host immune response.

In addition to immune evasion, the virus counteracts pro-apoptotic pathways induced by the host cell upon viral infection. Caspase 3 is a target of multiple viral miRNAs (miR-K12-1, miR-K12-3, and miR-K12-4-3p), and its inhibition desensitizes HHV-8-infected cells to caspase-induced apoptosis (Suffert et al. 2011). Similarly, miR-K12-10a suppresses TWEAK receptor (TWEAKR) expression, which limits TWEAK-induced caspase activation and apoptosis (Abend et al. 2010). TWEAKR inactivation also reduces production of pro-inflammatory cytokines IL-8/CXCL8 and MCP-1/CCL2 (Abend et al. 2010). BCLAF1, a transcriptional repressor, can be targeted by several of the HHV-8 microRNAs (miR-K12-5,

miR-K12-9, and miR-K12-10a/b), leading to decreased etoposide-induced apoptosis in PEL cells (Ziegelbauer et al. 2009). Finally, miR-K12-11, a homologue to cellular miR-155, alters expression of BACH1, which leads to a variety of phenotypic changes including upregulation of HMOX1 (increased cell survival), upregulation of xCT (increased infection permissivity in macrophages and endothelial cells), and protection against apoptosis mediated by reactive nitrogen species (Gottwein et al. 2007; Qin et al. 2010; Skalsky et al. 2007).

MicroRNAs encoded by HHV-8 also play significant roles in growth signaling and angiogenesis. Transforming growth factor beta (TGF β) signaling can be downregulated via the direct targeting of SMAD5 by miR-K12-11 (Liu et al. 2012); downregulation of TGF β signaling induces cell proliferation. It has been noted that HHV-8⁺ B-cell lines have decreased levels of miR-155, the cellular homologue of miR-K12-11; miR-K12-11 may compensate for the limited levels of miR-155 in these cells (Skalsky et al. 2007). Inhibition of miR-K12-11 was found to derepress TGF β signaling in HHV-8⁺ B cells (Liu et al. 2012). TGF β signaling can be modulated by thrombospondin 1 (THBS1), a target of HHV-8 miRNAs miR-K12-1, miR-K12-3, miR-K12-6, and miR-K12-11 (Samols et al. 2007). Thrombospondin 1 is an antiangiogenic factor, and its downregulation leads to repressed TGF β signaling (Samols et al. 2005). Thus, multiple viral microRNAs are capable of altering growth signaling and increasing angiogenesis to support the establishment of HHV-8-associated neoplasias. Additionally, viral miRNAs can alter the transcriptomes of endothelial cells and assist in cellular reprogramming. Both blood vessel endothelial cell (BEC) and lymphatic endothelial cell (LEC) expression markers are found in KS tissue, and the tissue can be reprogrammed toward the LEC or BEC fate under the appropriate stimuli. Specifically, miR-K12-6 and miR-K12-11 target the cellular transcription factor MAF (musculoaponeurotic fibrosarcoma oncogene homologue) (Hansen et al. 2010), which is found in LECs but not in BECs. Silencing of MAF by the microRNAs increases expression of BEC marker genes within the KS tissue. Targeting of MAF by miR-155 in CD4⁺ T cells has also been described (Rodriguez et al. 2007).

Several other studies have identified potential targets of viral microRNAs, though the validation of these targets is still ongoing. For example, Rbl2 (retinoblastoma-like protein 2) has been identified as a target of miR-K12-4-5p (Lu et al. 2010b). Rbl2 is an inhibitor of specific DNA methyltransferases (DNMT3a and 3b). Epigenetic changes have been observed following inhibition of Rbl2, but the consequences of these alterations are unclear (Lu et al. 2010b). Lastly, a largescale study utilizing a luciferase assay approach has identified several potential targets of various HHV-8 miRNAs. These targets include proteins with roles in vesicle trafficking, spliceosome assembly, transcription regulation, and cell cycle progression (Dolken et al. 2010). Validation of these protein targets is needed and will further enhance the understanding of the roles of miRNAs in HHV-8 biology and pathogenesis.

3 Novel Virus–Host Interactions via Lytic Activities

3.1 Viral Interleukin-6 (vIL-6)

In contrast to its direct autocrine role in PEL pathogenesis, vIL-6 is believed to contribute to KS and MCD predominantly via paracrine signaling. Newly infected cells and those undergoing lytic replication express vIL-6 as an early gene product, and vIL-6 is rapidly induced following RTA expression in these cells (Sun et al. 1999). The majority of HHV-8-infected cells in the KS lesion remain latently infected, but small subsets of cells are lytically active. This minority of cells expresses lytic proteins, including vIL-6, vGPCR, and K1; these proteins ultimately enhance the expression of cellular inflammatory and angiogenic cytokines (Mesri et al. 2010). For example, vIL-6 can induce expression of VEGF (Aoki and Tosato 1999), considered to be a key contributor to KS development. VEGF and cytokines such as IL-6, CXCL8, and bFGF are secreted from lytically active cells and can further activate nearby latently infected and uninfected cells in a paracrine fashion. The secreted proteins modulate survival of HHV-8-infected cells, angiogenesis (predominantly through VEGF), and recruitment of uninfected cells to the lesion site. Inflammatory cytokines (including IL-6) and angiogenic factors have been proposed to play a role in the initial development of KS (Ensoli and Sturzl 1998).

In MCD patients, levels of IL-6 are substantially higher in affected lymph nodes when compared to unaffected nodes of the same patient (Yoshizaki et al. 1989). Additionally, disease severity correlates with IL-6 levels, and when affected lymph nodes are resected, IL-6 levels decrease (Yoshizaki et al. 1989). Similarly, cell lines derived from HIV positive KS patients express IL-6, and KS tissue produces increased amounts of IL-6 compared to normal tissue (Miles et al. 1990). IL-6 antisense oligonucleotides were found to suppress the growth of KS cells from HIV positive patients as well as the production of IL-6, and addition of exogenous, recombinant IL-6 was able to restore growth and proliferation (Miles et al. 1990). An additional study observed substantially elevated levels of IL-6 produced by malignant plasma cells from MCD patients though not from other B-cell tumors (Burger et al. 1994). At the time of these discoveries, the mechanism of disease-associated IL-6 dysregulation was not understood. More recent reports have demonstrated that vIL-6 can induce the expression of IL-6 and VEGF in some cell types (Aoki et al. 1999; Mori et al. 2000). It is likely that vIL-6 also contributes directly to MCD. Additionally, vIL-6 downregulates CCL2 and inhibits the infiltration of neutrophils during acute infection of B cells (Fielding et al. 2005).

3.2 Viral CC-Chemokine Ligands (vCCLs)

The three HHV-8 chemokines, vCCL-1, vCCL-2, and vCCL-3, are encoded by ORFs K6, K4, and K4.1, respectively (Moore et al. 1996; Neipel et al. 1997b; Nicholas et al. 1997; Russo et al. 1996). All are expressed early during the lytic cycle (Jenner et al. 2001; Paulose-Murphy et al. 2001). vCCL-1 and vCCL-2 are most closely related structurally to cellular chemokines CCL3 and CCL4, while vCCL-3 shares significant primary sequence similarity with a number of CC-chemokines. However, the properties of the v-chemokines are distinct from those of their cellular counterparts. With respect to receptor usage, vCCL-1 is an agonist for CCR8; vCCL-2 signals through CCR3, CCR8, and potentially also CCR5;

vCCL-3 functionally targets CCR4 and XCR1 (Boshoff et al. 1997; Dairaghi et al. 1999; Luttichau 2008; Luttichau et al. 2007; Nakano et al. 2003; Stine et al. 2000). In addition, vCCL-2 binds several CCR- and CXCR-type chemokine receptors and CX₃CR1 as a neutral (non-signaling) ligand and effectively inhibits cellular chemokine activity through these receptors (Chen et al. 1998; Crump et al. 2001; Dairaghi et al. 1999; Kledal et al. 1997; Luttichau et al. 2001). The nature of the v-chemokine-targeted receptors suggests that they may mediate immune evasion via Th2 polarization and blocking of leukocyte trafficking, as has been demonstrated for vCCL-2 in in vivo experiments (Chen et al. 1998; Weber et al. 2001).

Apart from these immune evasion properties, each of the v-chemokines has been demonstrated to promote angiogenesis, in part via induction of VEGF (Boshoff et al. 1997; Liu et al. 2001; Stine et al. 2000). Like vIL-6, HHV-8 vCCLs have the potential to promote KS pathogenesis via paracrine signaling and may also play roles in PEL, where VEGF has been implicated as an important factor based on data from murine studies (Aoki and Tosato 1999; Ensoli and Sturzl 1998; Haddad et al. 2008). Additional contributions of vCCL-1 and vCCL-2 to pathogenesis may include pro-survival signaling via CCR8, demonstrated in uninfected and HHV-8-infected endothelial cells (Choi and Nicholas 2008). vCCL-1 and vCCL-2 were also found to promote survival of PEL and murine cell lines (Liu et al. 2001; Louahed et al. 2003). Unlike most (non-secreted) viral proteins, the v-chemokines have the potential to function in a paracrine manner. Therefore, these chemokines may promote cell survival of latently infected and uninfected cells surrounding those supporting lytic replication, thus contributing to viral pathogenesis. Nonetheless, an important aspect of the pro-survival activities of vCCL-1 and vCCL-2 is the positive contribution to productive replication via autocrine signaling. The endogenously produced v-chemokines inhibit lytic cycle-induced apoptosis and increase virus yields in HHV-8-infected endothelial cultures (Choi and Nicholas 2008). This activity involves CCR8 signaling-dependent suppression of lytic cycle stress-induced pro-apoptotic protein Bim, a powerful inhibitor of productive replication.

3.3 Viral G Protein-Coupled Receptor (vGPCR)

While not unique to HHV-8, the vGPCR encoded by this virus is structurally and functionally diverged from other gamma-2 herpesvirus vGPCRs and is strongly implicated as a paracrine contributor to KS development (Cannon 2007; Nicholas 2005; Rosenkilde et al. 2001; Verzijl et al. 2004). HHV-8 vGPCR is unusual in its promiscuous functional association with three classes of G α proteins (i, q, and 13) in addition to its direct association with and activation of the signaling protein SHP2 (Couty et al. 2001; Liu et al. 2004; Philpott et al. 2011; Shepard et al. 2001). Initial reports that vGPCR can function as a classical “autocrine” oncogene in in vitro and in vivo experimental systems employing vGPCR-transduced cell lines (Bais et al. 1998) implied that vGPCR may be expressed as a latent protein (enabling it to contribute directly to HHV-8 oncogenesis). However, no evidence of vGPCR latent expression has been forthcoming. Nonetheless, vGPCR can induce KS-like tumors in receptor-transduced mice, and this phenotype is supported despite only a minority of cells expressing vGPCR (Montaner et al. 2003; Yang et al. 2000). This can be explained by angiogenic, mitogenic, and inflammatory cellular cytokine induction via

vGPCR signaling, leading to local endothelial activation, proliferation, and tumorigenesis (Montaner et al. 2004). As stated above, cytokine dysregulation is considered to be the principle driver of KS disease. vGPCR is known to activate key factors, such as VEGF, bFGF, CXCL8, and IL-6, that are found in KS lesions and believed to promote and be required for KS development and progression (Bais et al. 1998; Cannon et al. 2003; Pati et al. 2001; Schwarz and Murphy 2001). Thus, vGPCR produced in a small minority of spontaneously reactivating endothelial cells may induce levels of cellular cytokines sufficient to promote KS. It should be noted that in animal models, vGPCR-expressing cells are able to cooperate with cells expressing latency genes v-cyclin and/or vFLIP to increase the frequency of KS achieved with inoculated vGPCR⁺ cells alone (Montaner et al. 2003). This supports the notion that both autocrine latent and paracrine lytic activities can function together in HHV-8-associated neoplasia.

3.4 Viral Interferon Regulatory Factors (vIRFs)

HHV-8 vIRFs 1-4 are specified by the genomic region encompassing ORFs K9 to K11; an equivalent locus (encoding 8 vIRFs) has been identified only in the closely related rhesus rhadinovirus (Alexander et al. 2000; Cunningham et al. 2003; Moore et al. 1996; Searles et al. 1999). All four of the vIRFs are expressed during lytic replication, but vIRF-1 and vIRF-3 are also expressed in PEL latency (Pozharskaya et al. 2004; Rivas et al. 2001). Additionally, vIRF-1 transcripts have been detected in KS cells using reverse transcription-polymerase chain reaction techniques (Dittmer 2003). As outlined above (Sect. 2.5), vIRF-3 is required for PEL cell viability (Wies et al. 2008); however, vIRF-1 depletion has no detectable influence on PEL cell growth or survival in culture (Y. Choi and J. Nicholas, unpublished data). The vIRFs appear to function primarily to evade host cell defenses against de novo infection and virus productive replication, which trigger cellular IRF and interferon signaling cascades leading to cell cycle arrest and pro-apoptotic signaling (Lee et al. 2009a; Offermann 2007). The vIRFs counter these cellular signals in several ways. IRF5 and IRF7 functional dimerization and promoter association are antagonized by direct binding of vIRF-3 to these cellular factors, and vIRF-3 also inhibits IRF3 activity (Joo et al. 2007; Wies et al. 2009). vIRF-1 mediates transcriptional repression of IRF-targeted genes by blocking IRF-directed promoter recruitment of p300/CBP via competitive binding to the transcriptional coactivators (Burysek et al. 1999a; Li et al. 2000; Lin et al. 2001; Seo et al. 2000; Zimring et al. 1998). Transcriptional repression of IRF1-, IRF3-, and ISGF3-targeted genes is mediated by vIRF-2, in part by activation of caspase 3-mediated destabilization of IRF3 (Areste et al. 2009; Burysek et al. 1999b; Fuld et al. 2006). In addition, vIRF-2 and vIRF-3 directly target and/or inhibit dsRNA-activated PKR kinase activity; this suppresses PKR promotion of protein translation and inhibits interferon signaling (Burysek and Pitha 2001; Esteban et al. 2003). Interestingly, vIRF-3 associates with and stabilizes the pro-angiogenic transcription factor HIF-1 α (Shin et al. 2008), and this could serve not only to promote endothelial cell survival but may also contribute to KS and PEL pathogenesis via induction of cytokines such as VEGF. vIRFs 1, 3, and 4 have been shown to inhibit p53 activity via (1) direct binding to the tumor suppressor (vIRF-1 and vIRF-3), (2) through interaction with p53-phosphorylating and p53-activating ATM kinase (vIRF-1), or (3) via stabilization of MDM2 (vIRF-4), which promotes ubiquitination and proteasomal degradation of p53 (Lee et al. 2009b; Nakamura et al. 2001; Rivas et al. 2001; Seo et al.

2001; Shin et al. 2006). Inhibitory interactions of vIRF-4 with deubiquitinase HAUSP have been reported to be involved in p53 destabilization (Lee et al. 2011). Therefore, p53 represents a major vIRF target that is important to control for efficient virus productive replication to occur. vIRF-4 also binds to CSL, the target of Notch, but the significance of this interaction is unclear (Heinzelmann et al. 2010).

vIRF-1 associates with and inhibits the activities of other cellular proteins involved in innate cellular responses to infection and the promotion of apoptosis. These targets include retinoic acid/interferon induced protein GRIM19 and TGF β receptor-activated transcription factors Smad3 (tumor suppressor) and Smad4 (co-Smad) (Angell et al. 2000; Ma et al. 2007; Seo et al. 2002, 2005). More recently, vIRF-1 has been found to bind directly to members of the so-called BH3-only protein (BOP) family (Choi and Nicholas 2010; Choi et al. 2012). BOPs are Bcl-2-related proteins that function to promote apoptosis either via inhibitory interactions with pro-survival members of the Bcl-2 family or by direct activation of apoptotic executioners Bax and Bak (Kuwana et al. 2005; Willis and Adams 2005). A region of vIRF-1 comprising residues 170-184 (BOP-binding domain, BBD) interacts with BOP BH3 domains, required for pro-apoptotic activities of these proteins, thereby mediating BOP inhibition (Choi and Nicholas 2010; Choi et al. 2012). vIRF-1 BBD, a predicted amphipathic α -helix, resembles the Bid BH3-inhibitory BH3-B domain of Bid and represents only the second example of a BH3-B-type BH3-inhibitory domain and therefore a novel viral mechanism of apoptotic inhibition. BBD-mediated interactions with BOPs are functionally important, as indicated by the following findings: (1) BBD-mutated vIRF-1 is less active than wild-type vIRF-1 in promoting productive replication and inhibiting apoptosis in lytically infected endothelial cells; (2) vIRF-1:BOP-disrupting BBD peptide causes significant inhibition of virus production in these cells; and (3) depletion of vIRF-1-targeted BOPs Bim or Bid leads to substantial increases in replicative titers (Choi and Nicholas 2010; Choi et al. 2012).

In summary, a wealth of published data indicates that the vIRFs of HHV-8 represent an effective panel of antiapoptotic proteins that promote productive replication via interactions with an important group of cellular proteins involved in host cell defenses against infection (summarized in Fig. 2).

3.5 K7-Encoded Viral Inhibitor of Apoptosis (vIAP)

In common with other gammaherpesviruses, HHV-8 specifies a homologue of cellular Bcl-2 proteins. However, HHV-8 encodes an additional BH-like domain-containing antiapoptotic protein that is a homologue of cellular survivin. This HHV-8 protein is referred to as K7 (corresponding to the encoding ORF) or viral inhibitor of apoptosis (vIAP). K7/vIAP is a membrane-associated protein that contains a putative mitochondrial-targeting signal and localizes to mitochondria, ER, and possibly other membranes as well (Feng et al. 2002; Wang et al. 2002). It has been reported that K7/vIAP binds to cellular Bcl-2 via its C-terminal BH2-like domain and to activated (proteolytically cleaved) caspase 3, bridging the two proteins and functionally inhibiting caspase 3 proteolytic activity (Wang et al. 2002). Interaction with and inhibition of terminal caspase 3 in the apoptotic cascade is analogous to the activities of cellular IAPs, which include survivin, XIAP, and cIAPs 1 and 2. However,

the interaction between K7/vIAP and Bcl-2 is a property not reported for its cellular counterparts. The functional and biological significance of this interaction remains to be determined. Nonetheless, K7/vIAP is able to inhibit pro-apoptotic signaling in transfected cells treated with agents such as Fas antibody and TNF- α , indicating its potential to act as a promoter of lytic replication via its pro-survival activity during lytic cycle-induced stress (Wang et al. 2002). K7/vIAP also interacts with calcium-modulating cyclophilin ligand (CAML), which regulates intracellular calcium ion concentrations (Bram and Crabtree 1994; Feng et al. 2002). The functional significance of this interaction is evident from the ability of wild-type but not CAML binding-refractory K7/vIAP to inhibit chemically-induced mitochondrial depolarization (i.e., apoptotic triggering) in transfected cells (Feng et al. 2002). Thus, in addition to its inhibitory binding to caspase 3, K7/vIAP appears to mediate apoptotic inhibition via CAML interaction. K7/vIAP also interacts with the cellular protein PLIC1 (protein-linking integrin-associated protein and cytoskeleton-1, also called ubiquilin), which associates with ubiquitin-conjugated proteins to inhibit their proteasomal degradation (Feng et al. 2004; Kleijnen et al. 2000; Wu et al. 1999). K7/vIAP appears to antagonize PLIC1 activity, thereby destabilizing ubiquitinated proteins, as demonstrated for p53 and NF- κ B-inhibitory I κ B (Feng et al. 2004). Together, the inhibitory interactions between K7/vIAP and cellular proteins PLIC1, caspase 3/Bcl-2, and CAML may promote cell survival during lytic replication and consequently enhance the efficiency of virus production.

4 Terminal Membrane Proteins

4.1 K1/Variable ITAM-Containing Protein (VIP)

The K1 ORF of HHV-8 is located at the left end of the genome and is collinear with other gammaherpesvirus genes encoding signaling membrane proteins. These include saimiri transformation-associated protein (STP) of herpesvirus saimiri (HVS), latency membrane protein-1 (LMP-1) of EBV, and the K1-homologous R1 receptor of rhesus rhadinovirus (Albrecht et al. 1992; Damania et al. 1999; Kaye et al. 1993; Lagunoff and Ganem 1997; Murthy et al. 1989). The K1 protein is a type I transmembrane signaling protein containing a functional immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic C-tail (Lagunoff et al. 2001; Lee et al. 1998a). Sequencing of K1 in different HHV-8 isolates identified an unusual degree of amino acid sequence variability in the extracellular regions of the encoded proteins (Nicholas et al. 1998; Zong et al. 1999), hence the naming of the K1 protein as variable ITAM-containing protein (VIP). While the functional significance of this variability has not been established, the K1 locus has served as a basis of epidemiological studies of HHV-8 strain distribution and infectivity (Hayward and Zong 2007; Mbulaiteye et al. 2006; Whitby et al. 2004). Based initially on the genomic position of K1 and subsequently on the constitutive signaling and transforming properties of K1/VIP, the protein was implicated as a potential contributor to HHV-8 pathogenesis. K1/VIP, like RRV R1, was able to substitute functionally for the positionally equivalent ORF1/STP of HVS in in vivo tumorigenesis assays and to promote cell growth and transformation in isolation (Lee et al. 1998b; Prakash et al. 2002). K1/VIP activation of the AKT pathway and consequent activation of mTOR (associated with cell growth) and the inactivation of pro-apoptotic GSK3, Bad, and forkhead transcription factors have been implicated in these activities (Tomlinson and Damania 2004; Wang et al. 2006). However, as K1 appears to be expressed

primarily or exclusively during lytic replication (Jenner et al. 2001; Lagunoff and Ganem 1997; Nakamura et al. 2003; Paulose-Murphy et al. 2001), its potential role in KS, PEL, and MCD may be restricted to paracrine effects of K1/VIP-induced cellular cytokines (see below) rather than direct effects suggested by initial functional analyses. While immunodetection of K1/VIP in KS and MCD tissues has been reported, this has not been associated with latently infected cells (Lee et al. 2003a; Wang et al. 2006). It should be noted, however, that in situ detection of K1 transcripts in some KS cells lacking detectable lytic marker (major capsid protein) mRNA expression suggests the possibility that K1/VIP may be expressed in at least some latently infected KS cells (Wang et al. 2006).

K1/VIP recruits and activates Src-family kinases, PI3K, and PLC γ to mediate signal transduction via several pathways by ligand-independent, constitutive signaling (Lagunoff et al. 2001; Lee et al. 2005, 1998a; Samaniego et al. 2001; Tomlinson and Damania 2004). It has been suggested that K1/VIP may contribute to HHV-8-associated disease, especially KS, by induction of cellular cytokines. K1/VIP-induced cytokines include pro-inflammatory IL-1 β , IL-6, and GM-CSF and angiogenic factors VEGF, CXCL8, and bFGF (Lee et al. 2005; Prakash et al. 2002; Samaniego et al. 2001; Wang et al. 2006). Contributions of the HHV-8 receptor to pathogenesis via cellular cytokine induction could theoretically occur during lytic replication or during latency. In KS, PEL, and MCD, small proportions of cells support lytic reactivation, enabling lytically expressed proteins, like K1, to exert paracrine influence on surrounding latently infected and uninfected cells (Aoki et al. 2003; Aoki and Tosato 2003; Ensoli et al. 2001).

4.2 K15-Encoded Membrane Protein

The K15-encoded protein in its full-length form is a twelve-transmembrane domain-containing signaling receptor. Like K1, K15 may play a role in pathogenesis via cytokine dysregulation, and it could conceivably contribute to malignant disease through pro-survival signaling during latency. Transcripts from the K15 locus are expressed predominantly during the lytic cycle, but some K15 products have been detected in resting (latent) PEL cultures (Choi et al. 2000; Glenn et al. 1999; Sharp et al. 2002). The issue is complex because the K15 primary transcript contains eight exons and can be differentially spliced; the resulting mRNAs and encoded proteins may be expressed differently based on cell type and whether the virus is in the latent or productive phase. All forms of K15 contain C-terminal protein sequences with functional signaling motifs (see below), but the protein isoforms differ in their complement of transmembrane domains. K15 transcripts and a 23-kDa protein isoform have been detected during latency in PEL cells, but K15 mRNA levels are induced considerably upon lytic reactivation (Choi et al. 2000; Glenn et al. 1999; Sharp et al. 2002; Tsai et al. 2009).

Full-length K15 protein has been detected in HHV-8 bacmid-containing HEK293 cells, though only after lytic induction with butyrate treatment (Brinkmann et al. 2007). However, the full-length protein has not been observed in cells naturally infected with HHV-8. The ability of immediate early, lytic trigger protein RTA to activate transcription from the K15 promoter is consistent with predominant lytic expression of K15 (Wong and Damania 2006). Nonetheless, uncertainty remains regarding the expression characteristics of K15 transcripts

and proteins and whether K15 receptor signaling could contribute to latency and HHV-8 neoplasia in an autocrine manner.

Signaling motifs in the cytoplasmic tail of all K15 isoforms and in both M and P allelic protein types (Poole et al. 1999) include two SH2- and single SH3- and TRAF-binding sites (Brinkmann et al. 2003; Choi et al. 2000; Glenn et al. 1999). SH2 binding-mediated interactions with Src-family kinases occur via the Y₄₈₁EEV motif, which is the primary site of K15 phosphorylation (Brinkmann et al. 2003; Choi et al. 2000). This, together with the SH3-binding sequence (PPLP), leads to inhibition of B-cell receptor (BCR) signaling. PPLP-motif interactions with intersectin 2 (endocytic adaptor protein) and with Src kinases (such as Lyn and Hck) are important for this activity (Lim et al. 2007; Pietrek et al. 2010). BCR inhibition by the K15 receptor parallels that of the collinearly encoded LMP-2 of EBV, and each is likely to promote latency by inhibiting lytic cycle reactivation promoted by BCR signaling. The Y₄₈₁EEV motif has been implicated in the activation of NF- κ B and mitogen-activated protein kinases (MAPKs) ERK and JNK, which occurs after Y₄₈₁ phosphorylation (Brinkmann and Schulz 2006; Choi et al. 2000; Pietrek et al. 2010). Interaction of the K15 receptor with TRAFs 1, 2, and 3 is likely to contribute to NF- κ B and MAPK signaling (Brinkmann and Schulz 2006; Glenn et al. 1999). The second tyrosine-containing motif, Y₄₃₂ASI, is not detectably phosphorylated, and its significance is uncertain. However, its interaction with apoptotic regulatory protein HAX-1 and ER and mitochondrial colocalization of HAX-1 with K15 suggest that the viral receptor may function to promote cell survival via this motif (Sharp et al. 2002).

Examination of the downstream effects of K15 signaling has provided insight into possible functions of the receptor in HHV-8 biology and its potential contributions to viral pathogenesis. In addition to suspected antiapoptotic activity via interaction with HAX-1, K15 can induce the expression of several antiapoptotic genes, including *A20*, *Bcl-2A1*, *Birc2*, and *Birc3* (Brinkmann et al. 2007). Induction of these genes may help promote cell survival during the lytic cycle, further enhancing productive replication. If K15 is expressed during latency, its pro-survival signaling could contribute to prolonged latent cell viability and maintenance of latency pools in vivo and to viral pathogenesis. On the other hand, the observed induction of cellular cytokines in K15-transduced cells suggests a mechanism by which K15 can affect surrounding cells (latently infected and uninfected) by paracrine signaling from lytically infected cells. K15-expressing latently infected cells could exert similar effects on the microenvironment. Cytokines induced by K15 receptor signaling include IL-6, CCL2, CXCL3, and CXCL8; each of these possesses angiogenic activity and has been implicated in KS pathogenesis (Brinkmann et al. 2007; Caselli et al. 2007; Ensoli and Sturzl 1998). It is intriguing that K15 also induces expression of genes representing downstream targets of angiogenic VEGF signaling. This would clearly implicate K15 as an autocrine contributor to pathogenesis should the receptor be expressed during latency, but such activity of K15 could also contribute to productive replication. Angiogenic targets of K15 include *Dscr-1* and *Cox-2* (Brinkmann et al. 2007). It is notable that Cox-2 has been reported to be induced during *de novo* and subsequent latent infection of endothelial cells by HHV-8, and Cox-2 is important for the production of several inflammatory and angiogenic factors (Sharma-Walia et al. 2010). Thus, pro-survival and paracrine-mediated pro-

angiogenic roles of K15 in HHV-8 lytic replication and pathogenesis seem likely, and there is potential for autocrine activity via pro-survival signaling contributing to latency and neoplasia if the receptor is latently expressed.

5 Summary

The discovery and study of HHV-8 has provided the opportunity to identify unique virus-specified activities encoded by proteins either not previously known among viruses or those not previously investigated or characterized in depth in other viral systems. HHV-8 has also provided a model for the identification and characterization of viral miRNAs, a new area of research that has provided unique and important insights into viral manipulation of host cell processes as part of normal virus biology and potentially in viral pathogenesis. The properties of the characterized protein and miRNA players in these processes have been described in detail, and several key points emerge. First, the notion that only autocrine, latent viral activities are relevant to virus-associated neoplasia needs revision, certainly in the case of KS and possibly for PEL and MCD. Paracrine factors (viral and/or cellular) produced during lytic replication can contribute to pro-proliferative, pro-survival, and other functions of pathogenic relevance. The latent and lytic viral proteins implicated in HHV-8 pathogenesis and their likely autocrine and paracrine contributions to disease are summarized in Fig. 3. Secondly, “lytic” and “latent” classifications for viral products are not as distinct as once thought. For example, vIL-6, vIRF-1, vIRF-3, K1, and K15 are clearly expressed maximally during productive replication, but there is evidence for their expression during latency as well in some cell types. Furthermore, it is notable that latently expressed vIL-6 and vIRF-3 are of demonstrable importance for PEL cell growth and viability. A third key point is that the virally encoded chemokines vCCL-1 and vCCL-2, while secreted during productive replication and thought to function to promote virus production via paracrine effects on the microenvironment (most notably to evade host immune responses), can also act directly on the cells in which they are produced to enhance virus production via antiapoptotic signaling. Such direct pro-replication activity has also been demonstrated for vGPCR. For the v-chemokines and vGPCR, it is possible that induced cellular cytokines may serve similar and/or additional activities to promote virus replication in an autocrine fashion as well as having broader effects on the host microenvironment. Finally, several of the HHV-8 proteins have multiple interactions with a broad range of host factors, a point summarized in Table 2 and exemplified by LANA and vIRF-1. Thus, viral proteins can have extraordinarily multifaceted activities via numerous protein interactions, and detailed characterization of these interactions and their functional effects is important for understanding their individual and combined contributions to virus biology and pathogenesis. Such characterization can potentially provide the basis for the development of new antiviral and therapeutic drugs designed to interfere with specific virus–host interactions of critical importance for viral replication or pathogenesis. This chapter has attempted to overview the various novel HHV-8–host interactions and related activities that contribute to these processes and that could perhaps be targeted in this way. The interactions described also illustrate the breadth and complexity of virus–host interactions and suggest that similar activities and mechanisms may be operative in other viral systems.

References

- Abend JR, Uldrick T, Ziegelbauer JM. Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi's sarcoma-associated herpesvirus microRNA prevents TWEAK-induced apoptosis and inflammatory cytokine expression. *J Virol*. 2010; 84:12139–12151. [PubMed: 20844036]
- Albrecht JC, Nicholas J, Cameron KR, Newman C, Fleckenstein B, Honess RW. Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59. *Virology*. 1992; 190:527–530. [PubMed: 1382344]
- Alexander L, Denekamp L, Knapp A, Auerbach MR, Damania B, Desrosiers RC. The primary sequence of rhesus monkey rhadinovirus isolate 26–95: sequence similarities to Kaposi's sarcoma-associated herpesvirus and rhesus monkey rhadinovirus isolate 17577. *J Virol*. 2000; 74:3388–3398. [PubMed: 10708456]
- Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. *Nat Med*. 1997; 3:917–921. [PubMed: 9256286]
- An FQ, Compitello N, Horwitz E, Sramkoski M, Knudsen ES, Renne R. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus modulates cellular gene expression and protects lymphoid cells from p16 INK4A-induced cell cycle arrest. *J Biol Chem*. 2005; 280:3862–3874. [PubMed: 15525642]
- An J, Sun Y, Sun R, Rettig MB. Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. *Oncogene*. 2003; 22:3371–3385. [PubMed: 12776188]
- Angell JE, Lindner DJ, Shapiro PS, Hofmann ER, Kalvakolanu DV. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. *J Biol Chem*. 2000; 275:33416–33426. [PubMed: 10924506]
- Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. *Blood*. 2003; 101:1535–1542. [PubMed: 12393476]
- Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, Tosato G. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. *Blood*. 1999; 93:4034–4043. [PubMed: 10361100]
- Aoki Y, Narazaki M, Kishimoto T, Tosato G. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. *Blood*. 2001; 98:3042–3049. [PubMed: 11698289]
- Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. *Blood*. 1999; 94:4247–4254. [PubMed: 10590069]
- Aoki Y, Tosato G. Targeted inhibition of angiogenic factors in AIDS-related disorders. *Curr Drug Targets Infect Disord*. 2003; 3:115–128. [PubMed: 12769789]
- Arete C, Mutocheluh M, Blackburn DJ. Identification of caspase-mediated decay of interferon regulatory factor-3, exploited by a Kaposi sarcoma-associated herpesvirus immunoregulatory protein. *J Biol Chem*. 2009; 284:23272–23285. [PubMed: 19553679]
- Arvanitakis L, Mesri EA, Nador RG, Said JW, Asch AS, Knowles DM, Cesarman E. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. *Blood*. 1996; 88:2648–2654. [PubMed: 8839859]
- Bais C, Santomaso B, Coso O, Arvanitakis L, Raaka EG, Gutkind JS, Asch AS, Cesarman E, Gershengorn MC, Mesri EA. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. *Nature*. 1998; 391:86–89. [PubMed: 9422510]
- Barbera AJ, Chodaparambil JV, Kelley-Clarke B, Joukov V, Walter JC, Luger K, Kaye KM. The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. *Science*. 2006; 311:856–861. [PubMed: 16469929]
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004; 116:281–297. [PubMed: 14744438]

- Bartoli M, Gu X, Tsai NT, Venema RC, Brooks SE, Marrero MB, Caldwell RB. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. *J Biol Chem*. 2000; 275:33189–33192. [PubMed: 10961983]
- Belanger C, Gravel A, Tomoiu A, Janelle ME, Gosselin J, Tremblay MJ, Flamand L. Human herpesvirus 8 viral FLICE-inhibitory protein inhibits Fas-mediated apoptosis through binding and prevention of procaspase-8 maturation. *J Hum Virol*. 2001; 4:62–73. [PubMed: 11437316]
- Bellare P, Ganem D. Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic reactivation. *Cell Host Microbe*. 2009; 6:570–575. [PubMed: 20006845]
- Bertin J, Armstrong RC, Otilie S, Martin DA, Wang Y, Banks S, Wang GH, Senkevich TG, Alnemri ES, Moss B, Lenardo MJ, Tomaselli KJ, Cohen JJ. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. *Proc Natl Acad Sci U S A*. 1997; 94:1172–1176. [PubMed: 9037025]
- Boshoff C, Endo Y, Collins PD, Takeuchi Y, Reeves JD, Schweickart VL, Siani MA, Sasaki T, Williams TJ, Gray PW, Moore PS, Chang Y, Weiss RA. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. *Science*. 1997; 278:290–294. [PubMed: 9323208]
- Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. *Science*. 2003; 300:2101–2104. [PubMed: 12829785]
- Boulanger MJ, Cow DC, Brevnova EE, Martick M, Sandford G, Nicholas J, Garcia KC. Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin 6. *J Mol Biol*. 2004; 335:641–654. [PubMed: 14672670]
- Bram RJ, Crabtree GR. Calcium signalling in T cells stimulated by a cyclophilin B-binding protein. *Nature*. 1994; 371:355–358. [PubMed: 7522304]
- Brinkmann MM, Glenn M, Rainbow L, Kieser A, Henke-Gendo C, Schulz TF. Activation of mitogen-activated protein kinase and NF-kappaB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. *J Virol*. 2003; 77:9346–9358. [PubMed: 12915550]
- Brinkmann MM, Pietrek M, Dittrich-Breiholz O, Kracht M, Schulz TF. Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus. *J Virol*. 2007; 81:42–58. [PubMed: 17050609]
- Brinkmann MM, Schulz TF. Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. *J Gen Virol*. 2006; 87:1047–1074. [PubMed: 16603506]
- Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R. NF-kappaB inhibits gammaherpesvirus lytic replication. *J Virol*. 2003; 77:8532–8540. [PubMed: 12857922]
- Bubman D, Guasparri I, Cesarman E. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. *Oncogene*. 2007; 26:4979–4986. [PubMed: 17310999]
- Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden JR, Gramatzki M. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. *Blood*. 1998; 91:1858–1863. [PubMed: 9490667]
- Burger R, Wendler J, Antoni K, Helm G, Kalden JR, Gramatzki M. Interleukin-6 production in B-cell neoplasias and Castleman's disease: evidence for an additional paracrine loop. *Ann Hematol*. 1994; 69:25–31. [PubMed: 8061104]
- Burysek L, Pitha PM. Latently expressed human herpesvirus 8-encoded interferon regulatory factor 2 inhibits double-stranded RNA-activated protein kinase. *J Virol*. 2001; 75:2345–2352. [PubMed: 11160738]
- Burysek L, Yeow WS, Lubyova B, Kellum M, Schafer SL, Huang YQ, Pitha PM. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. *J Virol*. 1999a; 73:7334–7342. [PubMed: 10438822]
- Burysek L, Yeow WS, Pitha PM. Unique properties of a second human herpesvirus 8-encoded interferon regulatory factor (vIRF-2). *J Hum Virol*. 1999b; 2:19–32. [PubMed: 10200596]

- Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. *Proc Natl Acad Sci U S A*. 2005; 102:5570–5575. [PubMed: 15800047]
- Cannon M. The KSHV and other human herpesviral G protein-coupled receptors. *Curr Top Microbiol Immunol*. 2007; 312:137–156. [PubMed: 17089796]
- Cannon M, Philpott NJ, Cesarman E. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. *J Virol*. 2003; 77:57–67. [PubMed: 12477810]
- Carbone A, Cilia AM, Gloghini A, Capello D, Perin T, Bontempo D, Canzonieri V, Tirelli U, Volpe R, Gaidano G. Primary effusion lymphoma cell lines harbouring human herpesvirus type-8. *Leuk Lymphoma*. 2000; 36:447–456. [PubMed: 10784388]
- Caselli E, Fiorentini S, Amici C, Di Luca D, Caruso A, Santoro MG. Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-dependent capillary-like structure formation: role of the IKK/NF-kappaB pathway. *Blood*. 2007; 109:2718–2726. [PubMed: 17138827]
- Chandriani S, Ganem D. Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. *J Virol*. 2010; 84:5565–5573. [PubMed: 20219929]
- Chang Y, Moore PS. Kaposi's Sarcoma (KS)-associated herpesvirus and its role in KS. *Infect Agents Dis*. 1996; 5:215–222. [PubMed: 8884366]
- Chaudhary PM, Jasmin A, Eby MT, Hood L. Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. *Oncogene*. 1999; 18:5738–5746. [PubMed: 10523854]
- Chen D, Cousins E, Sandford G, Nicholas J. Human herpesvirus 8 viral interleukin-6 interacts with splice variant 2 of vitamin K epoxide reductase complex subunit 1. *J Virol*. 2012; 86:1577–1588. [PubMed: 22130532]
- Chen D, Nicholas J. Structural requirements for gp80 independence of human herpesvirus 8 interleukin-6 (vIL-6) and evidence for gp80 stabilization of gp130 signaling complexes induced by vIL-6. *J Virol*. 2006; 80:9811–9821. [PubMed: 16973585]
- Chen D, Sandford G, Nicholas J. Intracellular signaling mechanisms and activities of human herpesvirus 8 interleukin-6. *J Virol*. 2009a; 83:722–733. [PubMed: 18987143]
- Chen S, Bacon KB, Li L, Garcia GE, Xia Y, Lo D, Thompson DA, Siani MA, Yamamoto T, Harrison JK, Feng L. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. *J Exp Med*. 1998; 188:193–198. [PubMed: 9653095]
- Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP. Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma-associated Herpesvirus Lymphomas. *J Virol*. 2010; 84:3898–3908. [PubMed: 20130056]
- Chen X, Cheng L, Jia X, Zeng Y, Yao S, Lv Z, Qin D, Fang X, Lei Y, Lu C. Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice. *Neoplasia*. 2009b; 11:1272–1284. [PubMed: 20019835]
- Choi JK, Lee BS, Shim SN, Li M, Jung JU. Identification of the novel K15 gene at the rightmost end of the Kaposi's sarcoma-associated herpesvirus genome. *J Virol*. 2000; 74:436–446. [PubMed: 10590133]
- Choi YB, Nicholas J. Autocrine and paracrine promotion of cell survival and virus replication by human herpesvirus 8 chemokines. *J Virol*. 2008; 82:6501–6513. [PubMed: 18434408]
- Choi YB, Nicholas J. Bim nuclear translocation and inactivation by viral interferon regulatory factor. *PLoS Pathog*. 2010; 6:e1001031. [PubMed: 20700448]
- Choi YB, Sandford G, Nicholas J. Human herpesvirus 8 interferon regulatory factor-mediated BH3-only protein Inhibition via Bid BH3-B mimicry. *PLoS Pathog*. 2012; 8(6):e1002748. [PubMed: 22685405]
- Chow D, He X, Snow AL, Rose-John S, Garcia KC. Structure of an extracellular gp130 cytokine receptor signaling complex. *Science*. 2001; 291:2150–2155. [PubMed: 11251120]

- Chugh P, Matta H, Schamus S, Zachariah S, Kumar A, Richardson JA, Smith AL, Chaudhary PM. Constitutive NF-kappaB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. *Proc Natl Acad Sci U S A*. 2005; 102:12885–12890. [PubMed: 16120683]
- Couty JP, Geras-Raaka E, Weksler BB, Gershengorn MC. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells. *J Biol Chem*. 2001; 276:33805–33811. [PubMed: 11448967]
- Crump MP, Elisseeva E, Gong J, Clark-Lewis I, Sykes BD. Structure/function of human herpesvirus-8 MIP-II (1–71) and the antagonist N-terminal segment (1–10). *FEBS Lett*. 2001; 489:171–175. [PubMed: 11165244]
- Cunningham C, Barnard S, Blackbourn DJ, Davison AJ. Transcription mapping of human herpesvirus 8 genes encoding viral interferon regulatory factors. *J Gen Virol*. 2003; 84:1471–1483. [PubMed: 12771416]
- Dairaghi DJ, Fan RA, McMaster BE, Hanley MR, Schall TJ. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. *J Biol Chem*. 1999; 274:21569–21574. [PubMed: 10419462]
- Damania B, Li M, Choi JK, Alexander L, Jung JU, Desrosiers RC. Identification of the R1 oncogene and its protein product from the rhadinovirus of rhesus monkeys. *J Virol*. 1999; 73:5123–5131. [PubMed: 10233975]
- Dittmer DP. Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays. *Cancer Res*. 2003; 63:2010–2015. [PubMed: 12727810]
- Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. *J Exp Med*. 1999; 190:1025–1032. [PubMed: 10510092]
- Dolken L, Malterer G, Erhard F, Kothe S, Friedel CC, Suffert G, Marcinowski L, Motsch N, Barth S, Beitzinger M, Lieber D, Bailer SM, Hoffmann R, Ruzsics Z, Kremmer E, Pfeffer S, Zimmer R, Koszinowski UH, Grasser F, Meister G, Haas J. Systematic analysis of viral and cellular microRNA targets in cells latently infected with human gamma-herpesviruses by RISC immunoprecipitation assay. *Cell Host Microbe*. 2010; 7:324–334. [PubMed: 20413099]
- Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, Monini P. Biology of Kaposi's sarcoma. *Eur J Cancer*. 2001; 37:1251–1269. [PubMed: 11423257]
- Ensoli B, Sturzl M. Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. *Cytokine Growth Factor Rev*. 1998; 9:63–83. [PubMed: 9720757]
- Esteban M, Garcia MA, Domingo-Gil E, Arroyo J, Nombela C, Rivas C. The latency protein LANA2 from Kaposi's sarcoma-associated herpesvirus inhibits apoptosis induced by dsRNA-activated protein kinase but not RNase L activation. *J Gen Virol*. 2003; 84:1463–1470. [PubMed: 12771415]
- Feng P, Park J, Lee BS, Lee SH, Bram RJ, Jung JU. Kaposi's sarcoma-associated herpesvirus mitochondrial K7 protein targets a cellular calcium-modulating cyclophilin ligand to modulate intracellular calcium concentration and inhibit apoptosis. *J Virol*. 2002; 76:11491–11504. [PubMed: 12388711]
- Feng P, Scott CW, Cho NH, Nakamura H, Chung YH, Monteiro MJ, Jung JU. Kaposi's sarcoma-associated herpesvirus K7 protein targets a ubiquitin-like/ubiquitin-associated domain-containing protein to promote protein degradation. *Mol Cell Biol*. 2004; 24:3938–3948. [PubMed: 15082787]
- Field N, Low W, Daniels M, Howell S, Daviet L, Boshoff C, Collins M. KSHV vFLIP binds to IKK-gamma to activate IKK. *J Cell Sci*. 2003; 116:3721–3728. [PubMed: 12890756]
- Fielding CA, McLoughlin RM, Colmont CS, Kovaleva M, Harris DA, Rose-John S, Topley N, Jones SA. Viral IL-6 blocks neutrophil infiltration during acute inflammation. *J Immunol*. 2005; 175:4024–4029. [PubMed: 16148151]
- Friberg J Jr, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. *Nature*. 1999; 402:889–894. [PubMed: 10622254]

- Fujimuro M, Hayward SD. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3 β . *J Virol*. 2003; 77:8019–8030. [PubMed: 12829841]
- Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young DB, Hayward GS, Hayward SD. A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. *Nat Med*. 2003; 9:300–306. [PubMed: 12592400]
- Fuld S, Cunningham C, Klucher K, Davison AJ, Blackbourn DJ. Inhibition of interferon signaling by the Kaposi's sarcoma-associated herpesvirus full-length viral interferon regulatory factor 2 protein. *J Virol*. 2006; 80:3092–3097. [PubMed: 16501120]
- Gaidano G, Pastore C, Gloghini A, Volpe G, Capello D, Polito P, Vaccher E, Tirelli U, Saglio G, Carbone A. Human herpesvirus type-8 (HHV-8) in haematopoietic neoplasia. *Leuk Lymphoma*. 1997; 24:257–266. [PubMed: 9156655]
- Glas R, Franksson L, Une C, Eloranta ML, Ohlen C, Orn A, Karre K. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. *J Exp Med*. 2000; 191:129–138. [PubMed: 10620611]
- Glenn M, Rainbow L, Aurade F, Davison A, Schulz TF. Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus. *J Virol*. 1999; 73:6953–6963. [PubMed: 10400794]
- Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. *Blood*. 2005; 105:2510–2518. [PubMed: 15572586]
- Gottwein E, Corcoran DL, Mukherjee N, Skalsky RL, Hafner M, Nusbaum JD, Shamulailatpam P, Love CL, Dave SS, Tuschl T, Ohler U, Cullen BR. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. *Cell Host Microbe*. 2011; 10:515–526. [PubMed: 22100165]
- Gottwein E, Cullen BR. A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest. *J Virol*. 2010; 84:5229–5237. [PubMed: 20219912]
- Gottwein E, Mukherjee N, Sachse C, Frenzel C, Majoros WH, Chi JT, Braich R, Manoharan M, Soutschek J, Ohler U, Cullen BR. A viral microRNA functions as an orthologue of cellular miR-155. *Nature*. 2007; 450:1096–1099. [PubMed: 18075594]
- Grossmann C, Ganem D. Effects of NF κ B activation on KSHV latency and lytic reactivation are complex and context-dependent. *Virology*. 2008; 375:94–102. [PubMed: 18321555]
- Grossmann C, Podgrabska S, Skobe M, Ganem D. Activation of NF- κ B by the latent vFLIP gene of Kaposi's sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. *J Virol*. 2006; 80:7179–7185. [PubMed: 16809323]
- Guaspari I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. *J Exp Med*. 2004; 199:993–1003. [PubMed: 15067035]
- Guaspari I, Wu H, Cesarman E. The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling. *EMBO Rep*. 2006; 7:114–119. [PubMed: 16311516]
- Haddad L, El Hajj H, Abou-Merhi R, Kfoury Y, Mahieux R, El-Sabban M, Bazarbachi A. KSHV-transformed primary effusion lymphoma cells induce a VEGF-dependent angiogenesis and establish functional gap junctions with endothelial cells. *Leukemia*. 2008; 22:826–834. [PubMed: 18094712]
- Hansen A, Henderson S, Lagos D, Nikitenko L, Coulter E, Roberts S, Gratrix F, Plaisance K, Renne R, Bower M, Kellam P, Boshoff C. KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. *Genes Dev*. 2010; 24:195–205. [PubMed: 20080955]
- Hayward GS, Zong JC. Modern evolutionary history of the human KSHV genome. *Curr Top Microbiol Immunol*. 2007; 312:1–42. [PubMed: 17089792]
- Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem J*. 2003; 374:1–20. [PubMed: 12773095]

- Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. *Biochem J.* 1998; 334:297–314. Pt 2. [PubMed: 9716487]
- Heinzelmann K, Scholz BA, Nowak A, Fossum E, Kremmer E, Haas J, Frank R, Kempkes B. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4/K10) is a novel interaction partner of CSL/CBF1, the major downstream effector of Notch signaling. *J Virol.* 2010; 84:12255–12264. [PubMed: 20861242]
- Hu S, Vincenz C, Buller M, Dixit VM. A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. *J Biol Chem.* 1997; 272:9621–9624. [PubMed: 9092488]
- Ishiyama T, Nakamura S, Akimoto Y, Koike M, Tomoyasu S, Tsuruoka N, Murata Y, Sato T, Wakabayashi Y, Chiba S. Immunodeficiency and IL-6 production by peripheral blood monocytes in multicentric Castleman's disease. *Br J Haematol.* 1994; 86:483–489. [PubMed: 8043430]
- Jenner RG, Alba MM, Boshoff C, Kellam P. Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. *J Virol.* 2001; 75:891–902. [PubMed: 11134302]
- Jones KD, Aoki Y, Chang Y, Moore PS, Yarchoan R, Tosato G. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. *Blood.* 1999; 94:2871–2879. [PubMed: 10515891]
- Joo CH, Shin YC, Gack M, Wu L, Levy D, Jung JU. Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. *J Virol.* 2007; 81:8282–8292. [PubMed: 17522209]
- Karim R, Tse G, Putti T, Scolyer R, Lee S. The significance of the Wnt pathway in the pathology of human cancers. *Pathology.* 2004; 36:120–128. [PubMed: 15203747]
- Kawa K. Epstein-Barr virus-associated diseases in humans. *Int J Hematol.* 2000; 71:108–117. [PubMed: 10745621]
- Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. *Proc Natl Acad Sci U S A.* 1993; 90:9150–9154. [PubMed: 8415670]
- Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. *Blood.* 2000; 96:2537–2542. [PubMed: 11001908]
- Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. *Blood.* 1995; 86:1243–1254. [PubMed: 7632928]
- Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, Power CA, Luttichau HR, Gerstoft J, Clapham PR, Clark-Lewis I, Wells TN, Schwartz TW. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. *Science.* 1997; 277:1656–1659. [PubMed: 9287217]
- Kleijnen MF, Shih AH, Zhou P, Kumar S, Soccio RE, Kedersha NL, Gill G, Howley PM. The hPLIC proteins may provide a link between the ubiquitination machinery and the proteasome. *Mol Cell.* 2000; 6:409–419. [PubMed: 10983987]
- Kliche S, Nagel W, Kremmer E, Atzler C, Ege A, Knorr T, Koszinowski U, Kolanus W, Haas J. Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. *Mol Cell.* 2001; 7:833–843. [PubMed: 11336706]
- Kovaleva M, Bussmeyer I, Rabe B, Grotzinger J, Sudarman E, Eichler J, Conrad U, Rose-John S, Scheller J. Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. *J Virol.* 2006; 80:8510–8520. [PubMed: 16912301]
- Krithivas A, Young DB, Liao G, Greene D, Hayward SD. Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells. *J Virol.* 2000; 74:9637–9645. [PubMed: 11000236]
- Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, Newmeyer DD. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. *Mol Cell.* 2005; 17:525–535. [PubMed: 15721256]
- Lagunoff M, Ganem D. The structure and coding organization of the genomic termini of Kaposi's sarcoma-associated herpesvirus. *Virology.* 1997; 236:147–154. [PubMed: 9299627]

- Lagunoff M, Lukac DM, Ganem D. Immunoreceptor tyrosine-based activation motif-dependent signaling by Kaposi's sarcoma-associated herpesvirus K1 protein: effects on lytic viral replication. *J Virol*. 2001; 75:5891–5898. [PubMed: 11390590]
- Lee BS, Connole M, Tang Z, Harris NL, Jung JU. Structural analysis of the Kaposi's sarcoma-associated herpesvirus K1 protein. *J Virol*. 2003a; 77:8072–8086. [PubMed: 12829846]
- Lee BS, Lee SH, Feng P, Chang H, Cho NH, Jung JU. Characterization of the Kaposi's sarcoma-associated herpesvirus K1 signalosome. *J Virol*. 2005; 79:12173–12184. [PubMed: 16160144]
- Lee H, Guo J, Li M, Choi JK, DeMaria M, Rosenzweig M, Jung JU. Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. *Mol Cell Biol*. 1998a; 18:5219–5228. [PubMed: 9710606]
- Lee H, Veazey R, Williams K, Li M, Guo J, Neipel F, Fleckenstein B, Lackner A, Desrosiers RC, Jung JU. Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. *Nat Med*. 1998b; 4:435–440. [PubMed: 9546789]
- Lee HR, Choi WC, Lee S, Hwang J, Hwang E, Guchhait K, Haas J, Toth Z, Jeon YH, Oh TK, Kim MH, Jung JU. Bilateral inhibition of HAUSP deubiquitinase by a viral interferon regulatory factor protein. *Nat Struct Mol Biol*. 2011; 18:1336–1344. [PubMed: 22056774]
- Lee HR, Kim MH, Lee JS, Liang C, Jung JU. Viral interferon regulatory factors. *J Interferon Cytokine Res*. 2009a; 29:621–627. [PubMed: 19715458]
- Lee HR, Toth Z, Shin YC, Lee JS, Chang H, Gu W, Oh TK, Kim MH, Jung JU. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. *J Virol*. 2009b; 83:6739–6747. [PubMed: 19369353]
- Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN. The nuclear RNase III Drosha initiates microRNA processing. *Nature*. 2003b; 425:415–419. [PubMed: 14508493]
- Lei X, Bai Z, Ye F, Xie J, Kim CG, Huang Y, Gao SJ. Regulation of NF-kappaB inhibitor IkkappaBalpha and viral replication by a KSHV microRNA. *Nat Cell Biol*. 2010; 12:193–199. [PubMed: 20081837]
- Li H, Komatsu T, Dezube BJ, Kaye KM. The Kaposi's sarcoma-associated herpesvirus K12 transcript from a primary effusion lymphoma contains complex repeat elements, is spliced, and initiates from a novel promoter. *J Virol*. 2002; 76:11880–11888. [PubMed: 12414930]
- Li M, Damania B, Alvarez X, Ogryzko V, Ozato K, Jung JU. Inhibition of p300 histone acetyltransferase by viral interferon regulatory factor. *Mol Cell Biol*. 2000; 20:8254–8263. [PubMed: 11027294]
- Liang D, Lin X, Lan K. Looking at Kaposi's Sarcoma-Associated Herpesvirus-Host Interactions from a microRNA Viewpoint. *Front Microbiol*. 2012; 2:271. [PubMed: 22275910]
- Lim CS, Seet BT, Ingham RJ, Gish G, Matskova L, Winberg G, Ernberg I, Pawson T. The K15 protein of Kaposi's sarcoma-associated herpesvirus recruits the endocytic regulator intersectin 2 through a selective SH3 domain interaction. *Biochemistry*. 2007; 46:9874–9885. [PubMed: 17696407]
- Lin CW, Tu PF, Hsiao NW, Chang CY, Wan L, Lin YT, Chang HW. Identification of a novel septin 4 protein binding to human herpesvirus 8 kaposin A protein using a phage display cDNA library. *J Virol Methods*. 2007; 143:65–72. [PubMed: 17383018]
- Lin R, Genin P, Mamane Y, Sgarbanti M, Battistini A, Harrington WJ Jr, Barber GN, Hiscott J. HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. *Oncogene*. 2001; 20:800–811. [PubMed: 11314014]
- Lin X, Liang D, He Z, Deng Q, Robertson ES, Lan K. miR-K12-7-5p encoded by Kaposi's sarcoma-associated herpesvirus stabilizes the latent state by targeting viral ORF50/RTA. *PLoS One*. 2011; 61:e16224. [PubMed: 21283761]
- Lindner SE, Sugden B. The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells. *Plasmid*. 2007; 58:1–12. [PubMed: 17350094]
- Liu C, Okruzhnov Y, Li H, Nicholas J. Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects. *J Virol*. 2001; 75:10933–10940. [PubMed: 11602733]

- Liu C, Sandford G, Fei G, Nicholas J. Galpha protein selectivity determinant specified by a viral chemokine receptor-conserved region in the C tail of the human herpesvirus 8 g protein-coupled receptor. *J Virol*. 2004; 78:2460–2471. [PubMed: 14963144]
- Liu J, Martin H, Shamay M, Woodard C, Tang QQ, Hayward SD. Kaposi's sarcoma-associated herpesvirus LANA protein downregulates nuclear glycogen synthase kinase 3 activity and consequently blocks differentiation. *J Virol*. 2007a; 81:4722–4731. [PubMed: 17314169]
- Liu J, Martin HJ, Liao G, Hayward SD. The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. *J Virol*. 2007b; 81:10451–10459. [PubMed: 17634226]
- Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. *J Biol Chem*. 2002; 277:13745–13751. [PubMed: 11830587]
- Liu Y, Sun R, Lin X, Liang D, Deng Q, Lan K. Kaposi's sarcoma-associated herpesvirus-encoded microRNA miR-K12-11 attenuates transforming growth factor beta signaling through suppression of SMAD5. *J Virol*. 2012; 86:1372–1381. [PubMed: 22013049]
- Louahed J, Struyf S, Demoulin JB, Parmentier M, Van Snick J, Van Damme J, Renauld JC. CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/CCL1 and vMIP-I. *Eur J Immunol*. 2003; 33:494–501. [PubMed: 12645948]
- Lu CC, Li Z, Chu CY, Feng J, Sun R, Rana TM. MicroRNAs encoded by Kaposi's sarcoma-associated herpesvirus regulate viral life cycle. *EMBO Rep*. 2010a; 11:784–790. [PubMed: 20847741]
- Lu F, Stedman W, Yousef M, Renne R, Lieberman PM. Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. *J Virol*. 2010b; 84:2697–2706. [PubMed: 20071580]
- Lubyova B, Kellum MJ, Frisancho JA, Pitha PM. Stimulation of c-Myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus. *J Biol Chem*. 2007; 282:31944–31953. [PubMed: 17728244]
- Lubyova B, Pitha PM. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. *J Virol*. 2000; 74:8194–8201. [PubMed: 10933732]
- Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. *Science*. 2004; 303:95–98. [PubMed: 14631048]
- Luttichau HR. The herpesvirus 8 encoded chemokines vCCL2 (vMIP-II) and vCCL3 (vMIP-III) target the human but not the murine lymphotactin receptor. *Virol J*. 2008; 5:50. [PubMed: 18426556]
- Luttichau HR, Johnsen AH, Jurlander J, Rosenkilde MM, Schwartz TW. Kaposi sarcoma-associated herpes virus targets the lymphotactin receptor with both a broad spectrum antagonist vCCL2 and a highly selective and potent agonist vCCL3. *J Biol Chem*. 2007; 282:17794–17805. [PubMed: 17403668]
- Luttichau HR, Lewis IC, Gerstoft J, Schwartz TW. The herpesvirus 8-encoded chemokine vMIP-II, but not the poxvirus-encoded chemokine MC148, inhibits the CCR10 receptor. *Eur J Immunol*. 2001; 31:1217–1220. [PubMed: 11298347]
- Ma X, Kalakonda S, Srinivasula SM, Reddy SP, Platanias LC, Kalvakolanu DV. GRIM-19 associates with the serine protease HtrA2 for promoting cell death. *Oncogene*. 2007; 26:4842–4849. [PubMed: 17297443]
- Mandel-Gutfreund Y, Kosti I, Larisch S. ARTS, the unusual septin: structural and functional aspects. *Biol Chem*. 2011; 392:783–790. [PubMed: 21824006]
- Marcos-Villar L, Lopitz-Otsoa F, Gallego P, Munoz-Fontela C, Gonzalez-Santamaria J, Campagna M, Shou-Jiang G, Rodriguez MS, Rivas C. Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. *J Virol*. 2009; 83:8849–8858. [PubMed: 19553342]
- Matta H, Chaudhary PM. Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). *Proc Natl Acad Sci U S A*. 2004; 101:9399–9404. [PubMed: 15190178]
- Matta H, Mazzacurati L, Schamus S, Yang T, Sun Q, Chaudhary PM. Kaposi's sarcoma-associated herpesvirus (KSHV) oncoprotein K13 bypasses TRAFs and directly interacts with the IkappaB

- kinase complex to selectively activate NF-kappaB without JNK activation. *J Biol Chem.* 2007; 282:24858–24865. [PubMed: 17597077]
- Mbulaiteye S, Marshall V, Bagni RK, Wang CD, Mbisa G, Bakaki PM, Owor AM, Ndugwa CM, Engels EA, Katongole-Mbidde E, Biggar RJ, Whitby D. Molecular evidence for mother-to-child transmission of Kaposi sarcoma-associated herpesvirus in Uganda and K1 gene evolution within the host. *J Infect Dis.* 2006; 193:1250–1257. [PubMed: 16586362]
- McCormick C, Ganem D. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. *Science.* 2005; 307:739–741. [PubMed: 15692053]
- McCormick C, Ganem D. Phosphorylation and function of the kaposin B direct repeats of Kaposi's sarcoma-associated herpesvirus. *J Virol.* 2006; 80:6165–6170. [PubMed: 16731955]
- Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. *Nat Rev Cancer.* 2010; 10:707–719. [PubMed: 20865011]
- Miles SA, Rezai AR, Salazar-Gonzalez JF, Vander Meyden M, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T, et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. *Proc Natl Acad Sci U S A.* 1990; 87:4068–4072. [PubMed: 1693429]
- Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, Gutkind JS. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. *Cancer Cell.* 2003; 3:23–36. [PubMed: 12559173]
- Montaner S, Sodhi A, Servitja JM, Ramsdell AK, Barac A, Sawai ET, Gutkind JS. The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. *Blood.* 2004; 104:2903–2911. [PubMed: 15231571]
- Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. *Science.* 1996; 274:1739–1744. [PubMed: 8939871]
- Mori Y, Nishimoto N, Ohno M, Inagi R, Dhepakson P, Amou K, Yoshizaki K, Yamanishi K. Human herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretion. *J Med Virol.* 2000; 61:332–335. [PubMed: 10861641]
- Munoz-Fontela C, Collado M, Rodriguez E, Garcia MA, Alvarez-Barrientos A, Arroyo J, Nombela C, Rivas C. Identification of a nuclear export signal in the KSHV latent protein LANA2 mediating its export from the nucleus. *Exp Cell Res.* 2005; 311:96–105. [PubMed: 16214130]
- Munoz-Fontela C, Marcos-Villar L, Gallego P, Arroyo J, Da Costa M, Pomeranz KM, Lam EW, Rivas C. Latent protein LANA2 from Kaposi's sarcoma-associated herpesvirus interacts with 14–3–3 proteins and inhibits FOXO3a transcription factor. *J Virol.* 2007; 81:1511–1516. [PubMed: 17108038]
- Muralidhar S, Pumfery AM, Hassani M, Sadaie MR, Kishishita M, Brady JN, Doniger J, Medveczky P, Rosenthal LJ. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. *J Virol.* 1998; 72:4980–4988. [PubMed: 9573267]
- Muralidhar S, Veytsmann G, Chandran B, Ablashi D, Doniger J, Rosenthal LJ. Characterization of the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) oncogene, kaposin (ORF K12). *J Clin Virol.* 2000; 16:203–213. [PubMed: 10738139]
- Murthy SC, Trimble JJ, Desrosiers RC. Deletion mutants of herpesvirus saimiri define an open reading frame necessary for transformation. *J Virol.* 1989; 63:3307–3314. [PubMed: 2545905]
- Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. *Cell Host Microbe.* 2009; 5:376–385. [PubMed: 19380116]
- Nakamura H, Li M, Zarycki J, Jung JU. Inhibition of p53 tumor suppressor by viral interferon regulatory factor. *J Virol.* 2001; 75:7572–7582. [PubMed: 11462029]
- Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, Jung JU. Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. *J Virol.* 2003; 77:4205–4220. [PubMed: 12634378]
- Nakano K, Isegawa Y, Zou P, Tadagaki K, Inagi R, Yamanishi K. Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded vMIP-I and vMIP-II induce signal transduction and chemotaxis in monocytic cells. *Arch Virol.* 2003; 148:871–890. [PubMed: 12721796]

- Neipel F, Albrecht JC, Ensser A, Huang YQ, Li JJ, Friedman-Kien AE, Fleckenstein B. Human herpesvirus 8 encodes a homolog of interleukin-6. *J Virol.* 1997a; 71:839–842. [PubMed: 8985427]
- Neipel F, Albrecht JC, Fleckenstein B. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? *J Virol.* 1997b; 71:4187–4192. [PubMed: 9151804]
- Nicholas J. Human gammaherpesvirus cytokines and chemokine receptors. *J Interferon Cytokine Res.* 2005; 25:373–383. [PubMed: 16022582]
- Nicholas J, Ruvolo VR, Burns WH, Sandford G, Wan X, Ciufo D, Hendrickson SB, Guo HG, Hayward GS, Reitz MS. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. *Nat Med.* 1997; 3:287–292. [PubMed: 9055855]
- Nicholas J, Zong JC, Alcendor DJ, Ciufo DM, Poole LJ, Sarisky RT, Chiou CJ, Zhang X, Wan X, Guo HG, Reitz MS, Hayward GS. Novel organizational features, captured cellular genes, and strain variability within the genome of KSHV/HHV8. *J Natl Cancer Inst Monogr.* 1998; 23:79–88. [PubMed: 9709308]
- Offermann MK. Kaposi sarcoma herpesvirus-encoded interferon regulator factors. *Curr Top Microbiol Immunol.* 2007; 312:185–209. [PubMed: 17089798]
- Okano M. Haematological associations of Epstein-Barr virus infection. *Baillieres Best Pract Res Clin Haematol.* 2000; 13:199–214. [PubMed: 10942621]
- Pati S, Cavois M, Guo HG, Foulke JS Jr, Kim J, Feldman RA, Reitz M. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. *J Virol.* 2001; 75:8660–8673. [PubMed: 11507211]
- Paudel N, Sadagopan S, Balasubramanian S, Chandran B. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen and Angiogenin Interact with Common Host Proteins, Including Annexin A2, Which Is Essential for Survival of Latently Infected Cells. *J Virol.* 2012; 86:1589–1607. [PubMed: 22130534]
- Paulose-Murphy M, Ha NK, Xiang C, Chen Y, Gillim L, Yarchoan R, Meltzer P, Bittner M, Trent J, Zeichner S. Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus). *J Virol.* 2001; 75:4843–4853. [PubMed: 11312356]
- Pearce M, Matsumura S, Wilson AC. Transcripts encoding K12, v-FLIP, v-cyclin, and the microRNA cluster of Kaposi's sarcoma-associated herpesvirus originate from a common promoter. *J Virol.* 2005; 79:14457–14464. [PubMed: 16254382]
- Petre CE, Sin SH, Dittmer DP. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. *J Virol.* 2007; 81:1912–1922. [PubMed: 17121789]
- Pfeffer S, Sewer A, Lagos-Quintana M, Sheridan R, Sander C, Grasser FA, van Dyk LF, Ho CK, Shuman S, Chien M, Russo JJ, Ju J, Randall G, Lindenbach BD, Rice CM, Simon V, Ho DD, Zavolan M, Tuschl T. Identification of microRNAs of the herpesvirus family. *Nat Methods.* 2005; 2:269–276. [PubMed: 15782219]
- Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander C, Tuschl T. *Science.* 2004; 304:734–736. [PubMed: 15118162]
- Philpott N, Bakken T, Pennell C, Chen L, Wu J, Cannon M. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor contains an immunoreceptor tyrosine-based inhibitory motif that activates Shp2. *J Virol.* 2011; 85:1140–1144. [PubMed: 21047965]
- Pietrek M, Brinkmann MM, Glowacka I, Enlund A, Havemeier A, Dittrich-Breiholz O, Kracht M, Lewitzky M, Saksela K, Feller SM, Schulz TF. Role of the Kaposi's sarcoma-associated herpesvirus K15 SH3 binding site in inflammatory signaling and B-cell activation. *J Virol.* 2010; 84:8231–8240. [PubMed: 20534855]
- Platt G, Carbone A, Mitnacht S. p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma. *Oncogene.* 2002; 21:1823–1831. [PubMed: 11896614]
- Poole LJ, Zong JC, Ciufo DM, Alcendor DJ, Cannon JS, Ambinder R, Orenstein JM, Reitz MS, Hayward GS. Comparison of genetic variability at multiple loci across the genomes of the major subtypes of Kaposi's sarcoma-associated herpesvirus reveals evidence for recombination and for

- two distinct types of open reading frame K15 alleles at the right-hand end. *J Virol.* 1999; 73:6646–6660. [PubMed: 10400762]
- Pozharskaya VP, Weakland LL, Zimring JC, Krug LT, Unger ER, Neisch A, Joshi H, Inoue N, Offermann MK. Short duration of elevated vIRF-1 expression during lytic replication of human herpesvirus 8 limits its ability to block antiviral responses induced by alpha interferon in BCBL-1 cells. *J Virol.* 2004; 78:6621–6635. [PubMed: 15163753]
- Prakash O, Tang ZY, Peng X, Coleman R, Gill J, Farr G, Samaniego F. Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene. *J Natl Cancer Inst.* 2002; 94:926–935. [PubMed: 12072546]
- Pyakurel P, Pak F, Mwakigonja AR, Kaaya E, Heiden T, Biberfeld P. Lymphatic and vascular origin of Kaposi's sarcoma spindle cells during tumor development. *Int J Cancer.* 2006; 119:1262–1267. [PubMed: 16615115]
- Qin Z, Freitas E, Sullivan R, Mohan S, Bacelieri R, Branch D, Romano M, Kearney P, Oates J, Plaisance K, Renne R, Kaleeba J, Parsons C. Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. *PLoS Pathog.* 2010; 6:e1000742. [PubMed: 20126446]
- Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. *Nat Med.* 2000; 6:1121–1127. [PubMed: 11017143]
- Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. *J Virol.* 2001; 75:429–438. [PubMed: 11119611]
- Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska EA, Vetrie D, Okkenhaug K, Enright AJ, Dougan G, Turner M, Bradley A. Requirement of bic/microRNA-155 for normal immune function. *Science.* 2007; 316:608–611. [PubMed: 17463290]
- Rosenkilde MM, Waldhoer M, Luttichau HR, Schwartz TW. Virally encoded 7TM receptors. *Oncogene.* 2001; 20:1582–1593. [PubMed: 11313905]
- Roth WK. HIV-associated Kaposi's sarcoma: new developments in epidemiology and molecular pathology. *J Cancer Res Clin Oncol.* 1991; 117:186–191. [PubMed: 2033087]
- Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). *Proc Natl Acad Sci U S A.* 1996; 93:14862–14867. [PubMed: 8962146]
- Sadagopan S, Sharma-Walia N, Veettil MV, Bottero V, Levine R, Vart RJ, Chandran B. Kaposi's sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis. *J Virol.* 2009; 83:3342–3364. [PubMed: 19158252]
- Sadagopan S, Valiya Veettil M, Paudel N, Bottero V, Chandran B. Kaposi's sarcoma-associated herpesvirus-induced angiogenin plays roles in latency via the phospholipase C gamma pathway: blocking angiogenin inhibits latent gene expression and induces the lytic cycle. *J Virol.* 2011; 85:2666–2685. [PubMed: 21209106]
- Sadagopan S, Veettil MV, Chakraborty S, Sharma-Walia N, Paudel N, Bottero V, Chandran B. Angiogenin functionally interacts with p53 and regulates p53-mediated apoptosis and cell survival. *Oncogene.* 2012; 31:4835–4847. [PubMed: 22266868]
- Sadler R, Wu L, Forghani B, Renne R, Zhong W, Herndier B, Ganem D. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. *J Virol.* 1999; 73:5722–5730. [PubMed: 10364323]
- Sakakibara S, Ueda K, Nishimura K, Do E, Ohsaki E, Okuno T, Yamanishi K. Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen. *J Virol.* 2004; 78:7299–7310. [PubMed: 15220403]
- Samaniego F, Pati S, Karp JE, Prakash O, Bose D. Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation? *J Natl Cancer Inst Monogr.* 2001; 28:15–23. [PubMed: 11158202]

- Samols MA, Hu J, Skalsky RL, Renne R. Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus. *J Virol*. 2005; 79:9301–9305. [PubMed: 15994824]
- Samols MA, Skalsky RL, Maldonado AM, Riva A, Lopez MC, Baker HV, Renne R. Identification of cellular genes targeted by KSHV-encoded microRNAs. *PLoS Pathogens*. 2007; 3:e65. [PubMed: 17500590]
- Sandford G, Choi YB, Nicholas J. Role of ORF74-encoded viral G protein-coupled receptor in human herpesvirus 8 lytic replication. *J Virol*. 2009; 83:13009–13014. [PubMed: 19793819]
- Schmidt K, Wies E, Neipel F. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression. *J Virol*. 2011; 85:4530–4537. [PubMed: 21345951]
- Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. *Cell*. 2003; 115:199–208. [PubMed: 14567917]
- Schwarz M, Murphy PM. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. *J Immunol*. 2001; 167:505–513. [PubMed: 11418689]
- Searles RP, Bergquam EP, Axthelm MK, Wong SW. Sequence and genomic analysis of a Rhesus macaque rhadinovirus with similarity to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. *J Virol*. 1999; 73:3040–3053. [PubMed: 10074154]
- Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. *Genes Dev*. 2000; 14:2501–2514. [PubMed: 11018017]
- Seo T, Lee D, Lee B, Chung JH, Choe J. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) binds to, and inhibits transactivation of, CREB-binding protein. *Biochem Biophys Res Commun*. 2000; 270:23–27. [PubMed: 10733899]
- Seo T, Lee D, Shim YS, Angell JE, Chidambaram NV, Kalvakolanu DV, Choe J. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM19, and inhibits interferon/retinoic acid-induced cell death. *J Virol*. 2002; 76:8797–8807. [PubMed: 12163600]
- Seo T, Park J, Choe J. Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 1 inhibits transforming growth factor-beta signaling. *Cancer Res*. 2005; 65:1738–1747. [PubMed: 15753369]
- Seo T, Park J, Lee D, Hwang SG, Choe J. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. *J Virol*. 2001; 75:6193–6198. [PubMed: 11390621]
- Shamay M, Krithivas A, Zhang J, Hayward SD. Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA. *Proc Natl Acad Sci U S A*. 2006; 103:14554–14559. [PubMed: 16983096]
- Sharma-Walia N, Paul AG, Bottero V, Sadagopan S, Veettil MV, Kerur N, Chandran B. Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. *PLoS Pathog*. 2010; 6:e1000777. [PubMed: 20169190]
- Sharp TV, Wang HW, Koumi A, Hollyman D, Endo Y, Ye H, Du MQ, Boshoff C. K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. *J Virol*. 2002; 76:802–816. [PubMed: 11752170]
- Shepard LW, Yang M, Xie P, Browning DD, Voyno-Yasenetskaya T, Kozasa T, Ye RD. Constitutive activation of NF-kappa B and secretion of interleukin-8 induced by the G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus involve G alpha(13) and RhoA. *J Biol Chem*. 2001; 276:45979–45987. [PubMed: 11590141]
- Shim WS, Ho IA, Wong PE. Angiopoietin: a TIE(d) balance in tumor angiogenesis. *Mol Cancer Res*. 2007; 5:655–665. [PubMed: 17634421]
- Shin YC, Joo CH, Gack MU, Lee HR, Jung JU. Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression. *Cancer Res*. 2008; 68:1751–1759. [PubMed: 18339855]

- Shin YC, Nakamura H, Liang X, Feng P, Chang H, Kowalik TF, Jung JU. Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1. *J Virol*. 2006; 80:2257–2266. [PubMed: 16474133]
- Skalsky RL, Samols MA, Plaisance KB, Boss IW, Riva A, Lopez MC, Baker HV, Renne R. Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. *J Virol*. 2007; 81:12836–12845. [PubMed: 17881434]
- Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, Beneke J, Pudney J, Anderson DJ, Ganem D, Haase AT. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. *J Virol*. 1997; 71:715–719. [PubMed: 8985403]
- Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M, Horwitz E, Prokocimer Z, Prichard M, Hahn G, Goldman-Wohl D, Greenfield C, Yagel S, Hengel H, Altuvia Y, Margalit H, Mandelboim O. Host immune system gene targeting by a viral miRNA. *Science*. 2007; 317:376–381. [PubMed: 17641203]
- Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanitsky N, Mandelboim M, Mandelboim O. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. *Nat Immunol*. 2008; 9:1065–1073. [PubMed: 18677316]
- Stine JT, Wood C, Hill M, Epp A, Raport CJ, Schweickart VL, Endo Y, Sasaki T, Simmons G, Boshoff C, Clapham P, Chang Y, Moore P, Gray PW, Chantry D. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. *Blood*. 2000; 95:1151–1157. [PubMed: 10666184]
- Sturzl M, Blasig C, Schreier A, Neipel F, Hohenadl C, Cornali E, Ascherl G, Esser S, Brockmeyer NH, Ekman M, Kaaya EE, Tschachler E, Biberfeld P. Expression of HHV-8 latency-associated T0.7 RNA in spindle cells and endothelial cells of AIDS-associated, classical and African Kaposi's sarcoma. *Int J Cancer*. 1997; 72:68–71. [PubMed: 9212225]
- Suffert G, Malterer G, Hausser J, Viilainen J, Fender A, Contrant M, Ivacevic T, Benes V, Gros F, Voinnet O, Zavolan M, Ojala PM, Haas JG, Pfeffer S. Kaposi's sarcoma herpesvirus microRNAs target caspase 3 and regulate apoptosis. *PLoS Pathog*. 2011; 7:e1002405. [PubMed: 22174674]
- Sun Q, Matta H, Lu G, Chaudhary PM. Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappaB activation. *Oncogene*. 2006; 25:2717–2726. [PubMed: 16418726]
- Sun R, Lin SF, Staskus K, Gradoville L, Grogan E, Haase A, Miller G. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. *J Virol*. 1999; 73:2232–2242. [PubMed: 9971806]
- Thomas M, Augustin HG. The role of the Angiopoietins in vascular morphogenesis. *Angiogenesis*. 2009; 12:125–137. [PubMed: 19449109]
- Thome M, Schneider P, Hofmann K, Fickenscher H, Meinel E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. *Nature*. 1997; 386:517–521. [PubMed: 9087414]
- Tomkowicz B, Singh SP, Cartas M, Srinivasan A. Human herpesvirus-8 encoded Kaposin: subcellular localization using immunofluorescence and biochemical approaches. *DNA Cell Biol*. 2002; 21:151–162. [PubMed: 12015894]
- Tomkowicz B, Singh SP, Lai D, Singh A, Mahalingham S, Joseph J, Srivastava S, Srinivasan A. Mutational analysis reveals an essential role for the LXXLL motif in the transformation function of the human herpesvirus-8 oncoprotein, kaposin. *DNA Cell Biol*. 2005; 24:10–20. [PubMed: 15684715]
- Tomlinson CC, Damania B. The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. *J Virol*. 2004; 78:1918–1927. [PubMed: 14747556]
- Tsai YH, Wu MF, Wu YH, Chang SJ, Lin SF, Sharp TV, Wang HW. The M type K15 protein of Kaposi's sarcoma-associated herpesvirus regulates microRNA expression via its SH2-binding motif to induce cell migration and invasion. *J Virol*. 2009; 83:622–632. [PubMed: 18971265]
- Umbach JL, Cullen BR. In-depth analysis of Kaposi's sarcoma-associated herpesvirus microRNA expression provides insights into the mammalian microRNA-processing machinery. *J Virol*. 2010; 84:695–703. [PubMed: 19889781]
- Verma SC, Lan K, Robertson E. Structure and function of latency-associated nuclear antigen. *Curr Top Microbiol Immunol*. 2007; 312:101–136. [PubMed: 17089795]

- Verschuren EW, Jones N, Evan GI. The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin. *J Gen Virol.* 2004; 85:1347–1361. [PubMed: 15166416]
- Verzijl D, Fitzsimons CP, Van Dijk M, Stewart JP, Timmerman H, Smit MJ, Leurs R. Differential activation of murine herpesvirus 68- and Kaposi's sarcoma-associated herpes-virus-encoded ORF74 G protein-coupled receptors by human and murine chemokines. *J Virol.* 2004; 78:3343–3351. [PubMed: 15016856]
- Wang HW, Sharp TV, Koumi A, Koentges G, Boshoff C. Characterization of an anti-apoptotic glycoprotein encoded by Kaposi's sarcoma-associated herpesvirus which resembles a spliced variant of human survivin. *EMBO J.* 2002; 21:2602–2615. [PubMed: 12032073]
- Wang HW, Trotter MW, Lagos D, Bourbouli D, Henderson S, Makinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. *Nat Genet.* 2004; 36:687–693. [PubMed: 15220918]
- Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B. immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. *Cancer Res.* 2006; 66:3658–3666. [PubMed: 16585191]
- Weber KS, Grone HJ, Rocken M, Klier C, Gu S, Wank R, Proudfoot AE, Nelson PJ, Weber C. Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. *Eur J Immunol.* 2001; 31:2458–2466. [PubMed: 11500830]
- Whitby D, Marshall VA, Bagni RK, Wang CD, Gamache CJ, Guzman JR, Kron M, Ebbesen P, Biggar RJ. Genotypic characterization of Kaposi's sarcoma-associated herpesvirus in asymptomatic infected subjects from isolated populations. *J Gen Virol.* 2004; 85:155–163. [PubMed: 14718630]
- Wies E, Hahn AS, Schmidt K, Viebahn C, Rohland N, Lux A, Schellhorn T, Holzer A, Jung JU, Neipel F. The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5. *J Biol Chem.* 2009; 284:8525–8538. [PubMed: 19129183]
- Wies E, Mori Y, Hahn A, Kremmer E, Sturzl M, Fleckenstein B, Neipel F. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. *Blood.* 2008; 111:320–327. [PubMed: 17890449]
- Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. *Curr Opin Cell Biol.* 2005; 17:617–625. [PubMed: 16243507]
- Wong EL, Damania B. Transcriptional regulation of the Kaposi's sarcoma-associated herpesvirus K15 gene. *J Virol.* 2006; 80:1385–1392. [PubMed: 16415016]
- Wu AL, Wang J, Zheleznyak A, Brown EJ. Ubiquitin-related proteins regulate interaction of vimentin intermediate filaments with the plasma membrane. *Mol Cell.* 1999; 4:619–625. [PubMed: 10549293]
- Yang TY, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M, Sullivan L, Jenh CH, Narula SK, Chensue SW, Lira SA. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. *J Exp Med.* 2000; 191:445–454. [PubMed: 10662790]
- Yoo J, Kang J, Lee HN, Aguilar B, Kafka D, Lee S, Choi I, Lee J, Ramu S, Haas J, Koh CJ, Hong YK. Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular endothelial cells by Kaposi's sarcoma herpes virus. *PLoS Pathog.* 2010; 6:e1001046. [PubMed: 20730087]
- Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. *Blood.* 1989; 74:1360–1367. [PubMed: 2788466]
- Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. *Oncogene.* 2003; 22:5108–5121. [PubMed: 12910248]
- Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. *Proc Natl Acad Sci U S A.* 2003; 100:9779–9784. [PubMed: 12902540]

- Zhang YJ, Bonaparte RS, Patel D, Stein DA, Iversen PL. Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus. *Mol Cancer Ther.* 2008; 7:712–720. [PubMed: 18347156]
- Zhao J, Punj V, Matta H, Mazzacurati L, Schamus S, Yang Y, Yang T, Hong Y, Chaudhary PM. K13 blocks KSHV lytic replication and deregulates vIL6 and hIL6 expression: a model of lytic replication induced clonal selection in viral oncogenesis. *PLoS One.* 2007; 2:e1067. [PubMed: 17957251]
- Zhong W, Wang H, Herndier B, Ganem D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. *Proc Natl Acad Sci U S A.* 1996; 93:6641–6646. [PubMed: 8692871]
- Ziech D, Franco R, Pappa A, Malamou-Mitsi V, Georgakila S, Georgakilas AG, Panayiotidis MI. The role of epigenetics in environmental and occupational carcinogenesis. *Chem Biol Interact.* 2010; 188:340–349. [PubMed: 20599843]
- Ziegelbauer JM, Sullivan CS, Ganem D. Tandem array-based expression screens identify host mRNA targets of virus-encoded microRNAs. *Nat Genet.* 2009; 41:130–134. [PubMed: 19098914]
- Zimring JC, Goodbourn S, Offermann MK. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. *J Virol.* 1998; 72:701–707. [PubMed: 9420276]
- Zong JC, Ciufu DM, Alcendor DJ, Wan X, Nicholas J, Browning PJ, Rady PL, Tying SK, Orenstein JM, Rabkin CS, Su IJ, Powell KF, Croxson M, Foreman KE, Nickoloff BJ, Alkan S, Hayward GS. High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations. *J Virol.* 1999; 73:4156–4170. [PubMed: 10196312]

Fig. 1.

ER-localized interactions and activities of vIL-6 in latently infected PEL cells. In the context of PEL latency, vIL-6 is expressed at low but functional levels and is largely sequestered in the ER compartment. Latently expressed vIL-6 supports PEL cell growth and viability. In vIL-6-depleted PEL cells, these activities can be complemented by ER-restricted (KDEL motif-tagged) transduced vIL-6, demonstrating sufficiency of ER-localized vIL-6 activity. The vIL-6 signal transducer, gp130, and a novel splice-variant protein, VKORC1v2, each bind vIL-6 within the ER, and depletion of each inhibits PEL cell growth and viability. Available evidence indicates that vIL-6 activity via each of these ER receptors occurs independently. While gp130-mediated activation of STAT and MAPK signaling has been detected in PEL cells, gp130 signaling (in contrast to effects on growth and survival) is not affected by VKORC1v2 depletion or by peptide-mediated disruption of vIL-6:VKORC1v2 interaction. Expression and pro-growth and pro-survival activities of vIL-6 in latently infected PEL cells suggest that the viral cytokine may contribute to latency maintenance in B cells and to PEL disease.

Fig. 2.

Summary of inhibitory interactions of vIRFs with cellular proteins. The particular vIRFs interacting with each target are indicated by the adjacent numbering (*red lettering*), and the effect of each interaction is indicated (*italics*). The activities of vIRF interactions are grouped into four general, overlapping biological categories, as indicated by the brackets and color coding. The vIRF:protein interactions and their significance are discussed fully in the text. (*Functional inhibition; no physical interaction detected)

Fig. 3.

Overview of potential contributions of HHV-8 proteins to virus-associated neoplasia. The general activities of relevance to HHV-8 malignant pathogenesis are indicated. Both latent and lytic proteins have the potential to contribute to disease, via autocrine and paracrine activities, respectively. Latent expression of signaling receptors encoded by ORFs K1 and K15 has so far not been demonstrated conclusively. Therefore, whether the autocrine activities detected experimentally (dotted lines) reflect direct roles of the receptors in HHV-8 pathogenesis remains uncertain (?). However, contributions of K1 and K15 receptors could contribute to neoplasia via induction of mitogenic, pro-survival, and angiogenic secreted cellular factors. This is also true of the viral chemokine receptor, vGPCR. The viral cytokines (lytic) are secreted and can act by both autocrine and paracrine mechanisms to influence cell growth and survival. These activities can promote virus replication (by autocrine signaling) in addition to contributing to viral pathogenesis (via paracrine effects). Latent expression of vIL-6 in PEL is likely to contribute to pathogenesis, mainly via intracrine signaling. vIRF-3 is also expressed during latency in PEL and like vIL-6 promotes PEL cell viability. The latency proteins have the potential to contribute to HHV-8-associated malignancies by direct autocrine effects on cell proliferation and survival by mechanisms typical of oncogenes and tumor suppressors (see the text). Kaposin B and vFLIP have the potential to function as promoters of cell proliferation and/or angiogenesis, but these functions have not been demonstrated directly (?)

Table 1

HHV-8-encoded microRNAs and their functions

Functional Class	Viral microRNA	Target	Activity/Function	References
Cell Cycle Regulation	miR-K12-1	p21	Inhibits cell cycle arrest	Gottwein and Cullen (2010)
Apoptosis	miR-K12-10a	TWEAKR	Reduced caspase activation	Abend et al. (2010)
	miR-K12-5, 9, 10	BCLAF1	Inhibits apoptosis	Ziegelbauer et al. (2009)
	miR-K12-1, 3, 4-3p	Caspase 3	Inhibits apoptosis	Suffert et al. (2011)
	miR-K12-11	BACH1	Pro-survival	Gottwein et al. (2007), Skalsky et al. (2007), Qin et al. (2010)
Latency Maintenance	miR-K12-3	NFIB	Inhibits RTA, Stabilizes latency	Lu et al. (2010a, b)
	miR-K12-5, 7-5p, 9	RTA	Stabilizes latency	Bellare and Ganem (2009), Lin et al. (2011), Lu et al. (2010a, b)
Growth Signaling	miR-K12-11	SMAD5	Limits TGF β signaling	Liu et al. (2012)
	miR-K12-6, 11	MAF	Cell fate reprogramming	Hansen et al. (2010)
Immune Evasion	miR-K12-7	MICB	Evasion from NK cells	Nachmani et al. (2009)
Angiogenesis	miR-K12-1, 3, 6, 11	THBS1	Increases angiogenesis	Samols et al. (2007)
Viral Replication	miR-K12-1	I κ B α	Limits viral replication	Lei et al. (2010)
Chromatin Modification	miR-K12-4-5p	Rb12	Global epigenetic modification	Lu et al. (2010a, b)
Unvalidated Targets	miR-K12-3	NHP2L1	Spliceosome assembly?	Dolken et al. (2010)
	miR-K12 cluster	LRRC8D	Unknown	Dolken et al. (2010)
	miR-K12 cluster	SEC15L	Vesicle trafficking?	Dolken et al. (2010)
	miR-K12-4-3	GEMIN8	mRNA splicing?	Dolken et al. (2010)
	miR-K12 cluster	ZNF684	Transcriptional regulation?	Dolken et al. (2010)

Functional Class	Viral microRNA	Target	Activity/ Function	References
	miR-K12 cluster	CDK5RAP1	CDK5 inhibitor?	Dolken et al. (2010)

Table 2

Virus–host protein interactions and their activities

Protein	Class	Target(s)	Activity/Function	References
LANA	Latent, replication	p53	Pro-survival	Friborg et al. (1999)
		Angiogenin/annexin A2	Pro-survival	Paudel et al. (2012)
		pRb	Pro-mitogenic	Radkov et al. (2000)
		GSK3 β	Pro-mitogenic	Fujimuro et al. (2003)
		c-Myc	Pro-mitogenic	Liu et al. (2007b)
		Histones H2A/B	Viral genome-chromosome tethering	Barbera et al. (2006)
		DNMT3a	Transcriptional repression	Shamay et al. (2006)
		SUV39H1	Transcriptional repression	Sakakibara et al. (2004)
K13/vFLIP	Latent, signaling	mSin3/SAP30/CIR	Transcriptional repression	Krithivas et al. (2000)
		IKK α/β	NF- κ B activation/survival	Matta et al. (2007)
		TRAF2/IKK γ ?	NF- κ B/Jnk activation	Guasparri et al. (2006)
Kaposin A	Latent, signaling	Procaspase-8	Inhibition of caspase activation/survival	Belanger et al. (2001)
		Cytoshesin-1, Septin 4 variant	GTPase-mediated signal transduction, activation of several signaling kinases; roles in survival/proliferation?	Kliche et al. (2001), Lin et al. (2007)
Kaposin B	Latent, mRNA reg.	MK2 kinase	MK2 activation, stabilization of ARE-containing mRNAs (e.g. IL-6, PROX1); potential pro-survival and/or mitogenic activity, endothelial reprogramming	McCormick and Ganem (2005)
vIL-6	Ligand, cytokine	gp130/gp80	STAT/MAPK activation; proliferation/survival, pro-inflammatory/angiogenic	Chow et al. (2001), Boulanger et al. (2004)
		VKORC1v2	Proliferation/survival (PEL), unknown mechanism	Chen et al. (2012)
vCCL-1	Ligand, chemokine	CCR8	Agonist, Th2 polarization;	Dairaghi et al. (1999), Choi and Nicholas (2008)

Protein	Class	Target(s)	Activity/Function	References
			pro-survival, promotes virus replication; pro-angiogenic	
vCCL-2	Ligand, chemokine	CCR3, CCR8, CCR5?	Agonist, Th2 polarization; pro-survival, promotes virus replication; pro-angiogenic	Choi and Nicholas (2008), Boshoff et al. (1997), Nakano et al. (2003)
		CCR5, CCR2, CCR10, CXCR4, CX3CR1, XCR1	Chemokine antagonist; pro-survival, promotes virus replication	Chen et al. (1998), Boshoff et al. (1997), Kledal et al. (1997), Luttichau et al. (2001), (2007)
vCCL-3	Ligand, chemokine	CCR4, XCR1	Agonist, Th2 polarization; pro-angiogenic	Stine et al. (2000), Luttichau et al. (2007)
vGPCR	Signaling receptor	Gα (i, q, 12/13), SHP2	Activation of various pro-survival and mitogenic signaling pathways; promotes virus replication; pro-angiogenic	Couty et al. (2001), Liu et al. (2004), Philpott et al. (2011), Shepard et al. (2001), Sandford et al. (2009)
vIRF-1	Innate response reg.	p53, ATM, p300/CBP, GRIM19, Smads 3/4, BOPs (incl. Bim & Bid), IRF1, IRF3	Pro-survival; IFN signaling inhibition	Burysek et al. (1999a), Choi et al. (2012), Li et al. (2000), Lin et al. (2001), Nakamura et al. (2001), Seo et al. (2001), (2002), (2005), Shin et al. (2006)
vIRF-2	Innate response reg.	PKR, IRF1, IRF2, p65, p300	IFN signaling inhibition	Burysek and Pitha (2001), Burysek et al. (1999b)
vIRF-3	Innate response reg.	p53, IRF3, IRF5, IRF7, 14-3-3, HIF-1α, Foxo3a	Pro-survival; IFN signaling inhibition; angiogenic signaling	Joo et al. 2007, Munoz-Fontela et al. (2007), Rivas et al. (2001), Shin et al. (2008), Weis et al. (2008)
vIRF-4	Innate response reg.	MDM2	Pro-survival (via p53 destabilization)	Lee et al. (2009b)
		HAUSP	Pro-survival (via p53 destabilization)	Lee et al. (2011)
		CSL	Unknown	Heinzelmann et al. (2010)
K7/vIAP	Apoptosis regulation	Bcl-2/caspase 3	Pro-survival	Wang et al. (2002)
		CAML	Pro-survival	Feng et al. (2002)
		PLIC	Pro-survival	Feng et al. (2004)
K1/VIP	Apoptosis regulation	Src kinases, PI3K, SHP2, PLCγ	Pro-survival/ mitogenic; pro-angiogenic/ inflammatory	Lee et al. (1998a), (2005)
K15	Signaling receptor	Src kinases, TRAFs, intersectin 2, HAX-1	Pro-survival/ mitogenic; pro-angiogenic	Brinkmann et al. (2003), Lim et al. (2007), Pietrek et al. (2010), Sharp et al. (2002)